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1. Abstract 
 
Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system. A number 
of pathological mechanisms could be responsible for acute demyelination and chronic tissue 
remodelling in MS, including inflammation, oxidative stress, microglia activation, and astrocyte 
infiltrates. In the present work, we aim to further explore the heterogeneity of MS pathogenesis on 
post mortem brains, and to evaluate the possibility to study MS pathogenesis by using magnetic 
resonance imaging (MRI) and peripheral blood biomarkers. 
 
In the first part of the study, we applied a data driven approach to classify MS patients in relation to 
the variety of pathological changes occurring in lesional and normal-appearing (NA) white matter 
(WM) and grey matter (GM), with subsequent clinical correlates. Tissue blocks from 16 MS brains 
were immunostained and quantified for neuro-axonal structures (NF200), myelin (SMI94), 
macrophages (CD68), B-lymphocytes (CD20), T-lymphocytes (CD3), cytotoxic T-lymphocytes (CD8), 
microglia (IBA1), astrocytes (GFAP), and mitochondrial damage. After semi-automatic registration 
of digitized histologic sections, regions-of-interest (ROIs) were manually defined in lesion and NA 
WM and GM. A latent class analysis was employed to characterize pathology subtypes in MS; 
different goodness of fit parameters (AIC, BIC, and G2 statistics) were used to identify the number 
of classes that better characterize the MS sub-populations. Profile 1 (active remodelling) was 
characterized by normal-appearing neuro-axonal structures and intact energetic metabolism, with 
high levels of macrophages/microglia and astrocytes. Profile 2 (mitochondrial dysfunction) was 
characterized by severely impaired mitochondrial function, along with demyelination and 
neuroaxonal loss, and ongoing inflammatory changes, mainly driven by cytotoxic T-cells (CD8+); 
patients in profile 2 presented with more severe symptoms at onset and faster disability accrual, 
when compared with other profiles. Profile 3 (inactive) was characterized by severe demyelination 
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and axonal loss, with similarly reduced mitochondrial function, without any concomitant 
pathological process contributing to further tissue remodelling and/or damage. The possibility to 
classify each patient depending on his/her prevalent pathology profile support the concept of MS 
immunopathological homogeneity within the same patient and heterogeneity between different 
patients, and could be used to better profile MS patients and individualize their treatment. 
 
In the second part of the study, we explored post mortem pathology-MRI correlates and specifically 
focused on an advanced MRI technique (magnetization transfer ratio -MTR-), ideally detecting 
myelin content. MTR is widely used in MS observational studies and clinical trials, but its 
pathological correlates remain unclear. MTR maps were acquired at 3 Tesla from sixteen fixed MS 
brains and four healthy controls. 101 tissue blocks were immunostained and quantified, as 
previously described. After semi-automatic registration of digitized histologic sections and MTR 
maps, ROIs were manually defined. Associations between MTR and each stain were explored using 
linear mixed regression models (with cassettes nested within patients); differences in the 
associations between ROIs were explored using interaction terms. Lower MTR was associated with 
lower levels of NF200, SMI94, CD68, IBA1 and GFAP, with higher levels of CD8 and greater 
mitochondrial damage; MTR was more strongly associated with SMI94 in GM than WM. In a 
multivariate linear mixed regression model including all ROIs and brains, SMI94 was the best 
correlate of MTR. Myelin immunostain intensity is the strongest correlate of MTR, especially when 
measured in the GM. However, the additional histological correlates of MTR have to be kept in mind 
when interpreting the results of MTR clinical studies and designing experimental trials in MS. 
 
Finally, we evaluated the possibility to study (and to modify) MS pathology in vivo, by using 
biomarkers in the peripheral blood. Considering that oxidative stress is a driver of MS pathology, we 
evaluated the effect of coenzyme Q10 (CoQ10) on laboratory markers of oxidative stress and 
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inflammation, and on MS clinical severity, and, then, calculated the sample size needed to detect 
significant variations to define most promising biomarkers. We included 60 relapsing-remitting MS 
patients treated with Interferon-Beta1a-44μg with CoQ10 for 3 months, and with Interferon-
Beta1a-44μg alone for 3 more months (open-label cross-over design). At baseline, 3- and 6-month 
visits, we measured markers of scavenging activity, oxidative damage and inflammation in the 
peripheral blood, and collected data on disease severity. After 3 months, CoQ10 supplementation 
was associated with improved scavenging activity (as mediated by uric acid), reduced intracellular 
reactive oxygen species production, reduced oxidative DNA damage, and shift towards a more anti-
inflammatory milieu in the peripheral blood (with higher IL-4 and IL-13, and lower Eotaxin, GM-CSF, 
HGF, IFN-γ, IL-1α, IL-2R, IL-9, IL-17F, MIP-1α, RANTES, TNF-α and VEGF). Also, CoQ10 
supplementation was associated with lower expanded disability status scale, fatigue severity scale, 
Beck's depression inventory, and visual analogic scale for pain. For sample size estimates, we used 
adjusted-beta-coefficients of observed 3-month variation for each laboratory measure (and 
respective standard deviation); we assumed that the observed variation was the highest achievable 
treatment effect (100%), and we estimated sample size for conservative treatment effects (e.g., 
70%), smaller than what observed. Setting 5% alpha-error and 80% power, low sample size 
requirements to detect 70% observed variation from a baseline pre-treatment timepoint to a 3-
month follow-up were found for IL-3 (n=1), IL-5 (n=1), IL-7 (n=4), IL-2R (n=4), IL-13 (n=6), IL-6 (n=14), 
IL-8 (n=22), IL-4 (n=23), RANTES (n=25), TNF-α (n=26), IL-1β (n=27), and uric acid (n=29). CoQ10 
supplementation improved scavenging activity, reduced oxidative damage, and induced a shift 
towards a more anti-inflammatory milieu, in the peripheral blood of relapsing-remitting MS patients 
treated with Interferon-Beta1a 44μg, along with clinical improvements. Peripheral biomarkers of 
oxidative stress and inflammation could be used in small proof-of-concept studies to quickly screen 
the mechanisms of action of new or already-existing medications for MS.  
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2. State of the art 
 
2.1 Multiple Sclerosis  
2.1.1. General definition 
Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous 
system (CNS) affecting approximately 2.5 million people worldwide, particularly young adults and 
women (C. A. Dendrou et al., 2015; Thompson et al., 2018). Typically, diagnosis occurs around the 
age of 30, with symptoms including motor difficulties, visual defects, cognitive issues, and 
bladder/bowel dysfunction (National Multiple Sclerosis Society, 2016). Patients may become 
wheelchair-bound some years after diagnosis and, ultimately, fatal complications such as infections 
and aspirational pneumonia are common (Rodríguez-Antigüedad Zarranz et al., 2014). 
 
2.1.2 Aetiology 
The causes of MS are unknown. Genetics represent only part of the disease risk, with genes being 
related primarily to proteins involved in the immune system regulation (Steri et al., 2017). Equally, 
environmental factors such as smoking and viruses (such as Epstein-Barr virus), are thought 
contribute to disease risk and progression (C. A. Dendrou et al., 2015; Magliozzi et al., 2013; M. 
Moccia, Lanzillo, Palladino, et al., 2015).  
 
2.1.3 Clinical phenotypes of MS 
MS can be divided into 3 main clinical types: relapsing remitting MS (RRMS), primary progressive 
MS (PPMS), and secondary progressive MS (SPMS). Patients may initially be diagnosed with RRMS, 
experiencing waxing and waning of symptoms. Partial or even full recovery can occur in remission 
stages. After 10-15 years of RRMS, 50% patients experience secondary progressive MS (SPMS), in 
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which symptoms no longer relapse and remit, but remain continuously present and progress, and 
patients experience clinical deterioration, perpetuating over time (Correale et al., 2017). Currently, 
there is no clear distinction between RRMS and SPMS, with transition occurring gradually over time 
(Lublin et al., 2014). This is contrasting with primary progressive MS (PPMS) in which patients 
experience progressive disease from onset, with or without inflammatory features (Lublin et al., 
2014) (Figure 1).  
 
Figure 1. Classification of MS, and disability over time. RRMS exhibits waxing and waning of neurological symptoms 
and disability. This may last years or even decades, before some progression to SPMS, with a constant degeneration of 
neurological function and increasing disability. PPMS refers to a similar degeneration, but from the onset, in the absence 
of a relapsing-remitting stage. Adapted from Dendrou et al. (2015). 
 
2.2 MS pathogenesis 
The pathogenesis of MS remains largely unknown. It is generally accepted that MS is an immune-
mediated disease with inflammatory leukocytes infiltrating the central nervous system (CNS) and 
ultimately leading to demyelination and neuro-axonal loss (Göbel et al., 2018). 
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Although initial events triggering MS are currently unknown, multiple layers of pathology are 
observed (autoimmunity, inflammation, tissue remodelling and, more recently recognised, 
mitochondrial dysfunction), overall resulting in demyelination and neuronal loss, with white matter 
(WM) and grey matter (GM) lesions and atrophy (Figure 2) (C. A. Dendrou et al., 2015; Magliozzi, 
Reynolds, et al., 2018; Martinez Sosa and Smith, 2017; Nicol et al., 2015). As such, a number of cells 
and mechanisms are involved in MS pathology within both normal-appearing (NA) and lesional WM 
and GM (M Moccia and Ciccarelli, 2017). 
 
Figure 2. White and grey matter lesions in MS. RRMS exhibits a high level of WM lesions, with GM lesions occurring 
more in progressive disease. Previously, GM lesions were largely undetected; development of MRI technology has now 
revealed their prevalence to a similar degree to WM lesions, with a prominent role in disability. Adapted from Dendrou 
et al., 2015 
 
2.2.1 Macrophages and microglia 
Macrophages are innate, phagocytic antigen-presenting cells (APCs), which can activate (and are 
activated by) lymphocytes, through the release of cytokines influencing lymphocyte activity and 
generating a pro-inflammatory loop in the brain parenchyma (C. Dendrou et al., 2015). 
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Progression of experimental autoimmune encephalomyelitis (EAE) (the most commonly used 
animal model of MS) is correlated to macrophage infiltration from the periphery to the CNS (Ajami 
et al., 2011). Some studies in EAE have implicated macrophages in the initial stages of demyelination 
and lesion formation, with microglia following in later stages (C. Dendrou et al., 2015). Indeed, 
microglia represent a late maturation stage of macrophages. Microglia act as the resident innate 
immune cells of the brain, with cytokine release, astrocyte and lymphocyte activation, and cellular 
debris scavenging (Prins et al., 2015). 
 
2.2.3 Astrocytes 
Formerly, astrocytes were only considered relevant to MS in the formation of glial scars after lesion 
resolution, whilst they are currently appreciated to have a more dynamic role. Astrocytes activated 
by inflammation are abundant in MS, advocating their involvement from early inflammatory stages 
(Ponath et al., 2018). In the long-term, astrocytes have been shown to heighten inflammation by 
releasing pro-inflammatory mediators, adhesion molecules, and chemokines, associated with 
microglia/macrophages migration into the parenchyma (Ponath et al., 2018). A continuous crosstalk 
between astrocytes and microglia/lymphocytes has been documented (Legroux and Arbour, 2015).  
 
2.2.4 T- and B-lymphocytes 
Different lymphocyte subsets interact among each other and contribute to the maintaining of a pro-
inflammatory milieu through the production of a variety of soluble mediators (e.g., cytokines and 
chemokines) (Göbel et al., 2018) (Figure 3).  
 
Pro-inflammatory T-lymphocytes are traditionally thought to be the key effectors in MS 
pathogenesis and, in keep with this, most approved MS therapies primarily target T cells by 
modulating their access and/or function within the CNS (Kinzel and Weber, 2016). T-lymphocytes 
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infiltrate the CNS in later stages of lesion formation (C. A. Dendrou et al., 2015), through direct 
activation of resident APCs (Bartholomäus et al., 2009). After invasion, these activated immune cells 
produce soluble mediators (e.g., cytokines and chemokines) that maintain a pro-inflammatory 
milieu compartmentalized within the CNS (Göbel et al., 2018).From a pathological perspective, CD4+ 
(helper) T cells are more concentrated in the peri-vascular cuff, whereas CD8+ (cytotoxic) T cells are 
widely distributed within the parenchyma (Reich et al., 2018).  
 
More recently, the dramatic success of B-cell-depleting antibodies in reducing MS clinical and 
radiological progression has shed light on the role of B-lymphocytes in MS pathogenesis (Gasperini 
et al., 2013; Greenfield and Hauser, 2018; Kinzel and Weber, 2016). After migrating to the CNS, B 
cell-derived plasma cells are responsible for the production of cerebrospinal fluid (CSF)-specific 
antibodies (oligoclonal bands) that have diagnostic and clinical relevance (Arrambide et al., 2018; 
Kinzel and Weber, 2016; Reich et al., 2018). Also, B-lymphocytes produce a set of cytokines, 
chemokines and survival factors, such as tumor necrosis factor alpha (TNF-α), interferon-gamma 
(IFN-γ), granulocyte macrophage-colony stimulating factor (GM-CSF) and interleukin (IL)-15, that 
contribute to developing and maintaining a B cell-friendly milieu (Cervantes-Gracia and Husi, 2018; 
Kinzel and Weber, 2016; Steri et al., 2017). B cells also secrete IL-6 that induces CD4+ T-17 
differentiation and inhibits the generation of regulatory T cells (Duddy et al., 2007). In the 
meanwhile, the ability of B cells to produce anti-inflammatory cytokines (such as IL-10) is inhibited 
(Kinzel and Weber, 2016). This could be important in more advanced disease stages, where 
infiltration of immune cells from the periphery is decreased (Howell et al., 2011), and B-lymphocytes 
accumulate in the meninges and subpial regions, in the form of follicle-like structures (Magliozzi et 
al., 2010). B-lymphocyte-rich follicle-like structures have been associated with a gradient of 
neuronal loss and demyelination, and with shorter time to wheelchair, and younger age at onset 
and death. (Howell et al., 2011; Magliozzi et al., 2007). 
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2.3 Magnetic resonance imaging in MS 
Advances in magnetic resonance imaging (MRI) techniques have enriched our understanding of the 
disease. Conventional MRI has become a pivotal tool for diagnosing and clinical monitoring of MS 
(Thompson et al., 2018). More recently, several quantitative MRI techniques have been developed, 
presenting with a higher specificity towards the pathological aspects of MS, when compared with 
conventional MRI (Filippi et al., 2012; Filippi and Rocca, 2011; M Moccia and Ciccarelli, 2017). 
 
2.3.1 Brain lesion count and volume 
Lesion measures are pivotal for MS diagnosis and clinical monitoring, and include the number of 
gadolinium-enhancing and new/enlarging T2 lesions, and their related volumes (Tur et al., 2018). 
Lesions are the best biomarker of active inflammation in MS, acting as a surrogate measure of 
clinical relapses, and allowing the screen for early disease activity in phase 2 clinical trials in RRMS 
(Sormani and Bruzzi, 2013). On the contrary, lesion-derived measures play a secondary -but not 
negligible- role in the study of progressive MS. In PPMS, the burden of T2-visible lesion load and of 
gadolinium-enhancing lesions is low, despite clinical severity (Miller and Leary, 2007), and seems to 
have only a minimal impact on the disability accrual over time (Khaleeli et al., 2010). 
 
2.3.2 Global and regional brain atrophy 
Brain atrophy is detectable on MRI scans from the earliest clinical stages of MS and is a biomarker 
of irreversible neurodegenerative processes (Ontaneda and Fox, 2017). Global brain atrophy has 
been associated with the degree of disability in large cohorts of both RR and progressive MS 
(Khaleeli et al., 2008; Rovaris et al., 2008). Besides, improvements in MRI post-processing have 
allowed to segment WM and GM (both cortical and deep) separately, allowing refinement of 
association with clinical features (Fisniku et al., 2008; Magliozzi, Reynolds, et al., 2018; Rocca et al., 
2012; Scalfari et al., 2018). Regional volumes might show a greater change over time (Eshaghi, 
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Marinescu, et al., 2018; Eshaghi, Prados, et al., 2018; Kapoor et al., 2010), resulting in higher 
sensitivity and smaller sample size when compared with global measures (Healy et al., 2009). 
Intriguingly, brain atrophy has not been associated with relapse risk in RRMS, suggesting that 
atrophy is probably driven more by (possibly independent) neurodegenerative changes than 
inflammatory lesions, which further support the use of this measure in progressive MS (Moccia, 
Quarantelli, et al., 2017; Ontaneda and Fox, 2017). 
 
2.3.3 Advanced MRI techniques 
Conventional neuroimaging techniques lack specificity with regard to different pathophysiological 
substrates of MS, and are not able to explain the heterogeneous and long-term clinical evolution of 
the disease (Bodini et al., 2015; Friese et al., 2014; Popescu et al., 2013; Sormani et al., 2014). 
Advanced MRI techniques, such as magnetization transfer ratio (MTR), diffusion tensor imaging 
(DTI), and magnetic resonance spectroscopy (MRS), may provide higher pathological specificity for 
the more destructive aspects of the disease (i.e., demyelination and neuroaxonal loss), and be more 
closely associated with clinical correlates (Barkhof et al., 2009; Enzinger et al., 2015). Moreover, 
functional MRI (fMRI) is contributing to the definition of the role of cortical reorganization after MS 
tissue damage (Rocca et al., 2012). 
 
Among a variety of quantitative MRI measures, the MTR calculated from magnetization transfer 
(MT) imaging has emerged as a measure of particular interest. MTR values reflect the efficiency of 
the magnetization exchange between mobile protons in tissue water and those bound to the 
macromolecules, such as myelin. MTR might have a potential role in correlating with clinical and 
cognitive disability (Z. Khaleeli et al., 2007; Ranjeva et al., 2005), predicting clinical progression (Z 
Khaleeli et al., 2007; Khaleeli et al., 2008), and monitoring treatment efficacy in MS (van den 
Elskamp et al., 2010). In view of this, MTR has been included in several clinical trials in progressive 
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MS and has been measured in GM, WM, T2 lesions, putamen, thalamus and optic nerve 
(ClinicalTrials.gov, 2016; Connick et al., 2012; Fox et al., 2016; Romme Christensen et al., 2014).  
 
MRI alone provides only indirect information about the underlying pathological changes of the 
disease (Filippi et al., 2012). Therefore, to shed light on the exact pathological substrates reflected 
by MRI abnormalities, correlative pathological and further MRI studies are certainly needed 
(Moccia, de Stefano, et al., 2017). 
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3. Objectives 
 
The present study aims to explore the pathogenesis of MS on post mortem brain samples and in 
vivo, and, in particular, has three main objectives: 
 
1. Defining the pathology of MS with latent-profile models 
In the first part of the study, we analysed post mortem MS brain samples with a data driven 
approach in order to define pathology profiles of MS, with their possible clinical correlates. 
 
2. Pathological correlates of MTR in MS 
The second part of the study is based on post mortem MRI and its pathological correlates. In 
particular, we explored pathological correlates of an advanced MRI technique (MTR), ideally 
designed to detect myelin content, but possibly affected by the variety of MS pathology. 
 
3. Peripheral markers of oxidative stress and inflammation in MS 
Finally, we explored the feasibility of studying (and modifying) oxidative stress and 
inflammation in vivo by measuring biomarkers in the peripheral blood.  
 
  
 18 
4. Defining the pathology of multiple sclerosis with latent-profile models 
 
4.1 Introduction 
Classifications of MS ought to reflect its clinical course and, ideally, its pathological background. 
Accurate patient profiling is crucial for prognostic and therapeutic purposes in the clinical practice, 
and to recruit homogeneous populations in observational studies and clinical trials designed to 
address specific questions (Broman et al., 1965; Ntranos and Lublin, 2016). 
 
Current clinical classification of MS phenotypes is based on the assessment of inflammatory activity 
(relapses or active lesions on MRI), and of progression of disability (either together or separately) 
(Fred D. Lublin et al., 2014). This descriptive classification fits perfectly with currently-available 
disease modifying treatments (DMTs) for MS that are specifically able to target inflammation 
(Ntranos and Lublin, 2016), and has been a cornerstone to prove their efficacy on progressive 
patients with inflammatory features (Hughes et al., 2018; Kappos et al., 2018; Montalban et al., 
2017). 
 
In past decades, a number of pathological classifications have been proposed based on the degree 
of demyelination and immune cell interactions in lesional and peri-lesional white matter (WM) (Bö 
et al., 1994; Bruck et al., 1995; Kuhlmann et al., 2017; Lassmann et al., 1998; Lucchinetti et al., 2000; 
Sanders et al., 1993; Van Der Valk and De Groot, 2000). These qualitative classifications were 
thought to depict the temporal evolution of demyelination and inflammation (e.g., active lesions 
progressively becoming inactive), and shared common pathogenetic elements (Kuhlmann et al., 
2017; Van Der Valk and De Groot, 2000), that have been used for studying potential therapeutic 
targets (Lassmann, 2017). However, patterns of demyelination and inflammation across different 
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lesions were consistently heterogenous between MS patients, but remained substantially 
homogenous within the same patient, also in serial biopsies (Breij et al., 2008; Lucchinetti et al., 
2000; Metz et al., 2014). These findings suggest that different subgroups of MS patients share similar 
pathogenetic mechanisms leading to demyelinating inflammatory lesions (Breij et al., 2008; 
Lucchinetti et al., 2000).  
 
A variety of pathogenetic mechanisms occurs in MS along with inflammation and demyelination 
(e.g., axonal loss, astrocyte reaction, mitochondrial damage), and involves both lesional and NA 
tissue in the WM and GM (Haider et al., 2016; Kawachi and Lassmann, 2017; Lassmann, 2018). Thus, 
assuming intraindividual immunopathological homogeneity, we hypothesize that MS patients can 
be classified in relation to the variety of pathological changes occurring in lesional and NA WM and 
GM, with subsequent clinical correlates. The present study aims to: 1) define pathology profiles of 
MS with a data-driven approach (latent-profile analysis); 2) evaluate pathological features of each 
pathology profile; 3) evaluate clinical correlates of each pathology profile. 
 
4.2 Methods 
4.2.1 Subjects 
Tissue for this study was provided by the United Kingdom MS Tissue Bank at the Imperial College 
London, under ethical approval from the National Research Ethics Committee. The study followed 
Human Tissue Act guidelines. All MS patients (n=16) had provided informed consent to donate tissue 
for MS research. Informed consent of the next of kin of the healthy subject was obtained before the 
inclusion of the tissue in this study. Demographic and clinical characteristics are reported in Table 
1. 
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4.2.2 Tissue handling and immunohistochemistry 
From each brain, a single coronal cut through mammillary bodies was done to separate brain into 
anterior and posterior halves. Then, 1 cm-thick coronal slices were cut through the entire brain using 
the 1 cm guide and, for the present study, the second slice posterior to the mammillary bodies 
towards the occipital pole was included. Slices were immersed in 10% buffered formaldehyde 
solution for a minimum of seven days, allowing full fixation. 
 
After scanning, brain slices were sectioned into different 5 mm-tick tissue blocks (each 
approximately 20×30 mm in size) (85 blocks in 16 cases, on average 5.3 blocks per brain slice) (Fig 
1A). Serial sections were cut through the block at 5 μm section thickness using the Tissue-Tek 
AutoSection automated microtome (Sakura Finetek). 
 
Cassettes were paraffin-embedded and immunostained by IQPath under the supervision of Prof 
Sebastian Brandner (UCL Queen Square Institute of Neurology, University College London). 
Immunostaining was performed using the Ventana Discovery XT instrument and the DAB Map 
detection Kit (760-124), in compliance with manufacturer instructions. Cassettes were 
immunostained for neuro-axonal structures (NF200), myelin (SMI94), macrophages (CD68), 
microglia (IBA1), B-lymphocytes (CD20), T-lymphocytes (CD3), cytotoxic T-lymphocytes (CD8), 
astrocytes (GFAP), and mitochondrial activity (COX4, VDAC). Slides were counterstained with 
hematoxylin (HE). Positive and negative controls were included initially when optimizing the stains 
and, then, only positive controls were included for antigens not expected to be present abundantly 
in the tissue. Details of immunostains are reported in Table 2. 
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Immunostained slides were digitalized as 8-bit RGB images at 40× magnification using a Leica 
SCN400F slide scanner (Leica Microsystems), and analysed with Definiens Tissue Studio software 3.6 
(Definiens AG, Munich, Germany) (Patodia et al., 2018), with a resolution of 5× for tissue 
identification and a resolution of 10× for stain analysis, taking care to exclude any artefacts (e.g., 
breaks in the section). Images were segmented into pixels of 250×250 µm2 (0.0625 mm2). The 
intensity threshold for positive labelling was set separately for each immunostain, using an 
automatic histogram method accounting for variation in background stain levels (Otsu, 1979). 
Separate thresholds were set for HE counterstaining which allowed identification of nuclei. 
 
For each pixel, immunostain intensity and its coordinates were exported in comma-separated values 
(CSV) files, including brown intensity for immunostains and blue for HE. 
 
4.2.3 Registration 
To align histology spatially, a subject-wise space was created by group-wise registration of digitized 
histological images, via consecutive rounds of rigid, affine and non-linear registrations, with 
NiftyReg (version 1.3.9) (Modat et al., 2010, 2014; Pichat et al., 2018). 
 
4.2.4 Image analysis and data extraction 
ROIs were manually delineated on the co-registered histology with 3D Slicer (version 4.4.0). The 
detection of ROIs was primarily guided by histological images with higher contrast (e.g., NF200, 
SMI94, GFAP, COX4, VDAC). ROI area was variable depending on the amount of included tissue. The 
following ROIs were drawn (number of included ROIs is reported): NAWM (n=98), WM lesions 
(n=62), cortical NAGM (n=89), and cortical GM lesions (n=53) (on average 2.9±1.8 ROIs per block). 
Overall, 302 records (from different cases/controls, tissue blocks, and ROIs) were included in the 
statistical models. 
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Mean immunostain intensity (percentage of stained area) and ROI area were extracted for each ROI 
using FSL (version 5.0.9). For data analysis, the intensity of mitochondrial immunostains was 
combined as follows: percentage of damaged mitochondria = (VDAC-COX4)/VDAC (Roman et al., 
2005; Shoshan-Barmatz et al., 2010). 
 
4.2.5 Clinical variables 
Clinical variables were extracted by a neurologist blinded to the pathological analysis, from 
retrospective review of detailed patients’ records. Clinical variables were: functional system 
involved at onset (cerebellar symptoms, optic neuritis, pyramidal dysfunction, sensory symptoms, 
spinal cord motor dysfunction), clinical course at death (SP or PPMS), time to wheelchair 
dependence (expanded disability status scale -EDSS- 7.0 equivalent, measured as the time from 
onset to wheelchair dependence), and time to death (EDSS 10 equivalent, measured as the time 
from onset to death) (Howell et al., 2011). Causes of death were MS-related (Cutter et al., 2015). 
Full data are reported in Table 1. 
 
4.2.6 Statistics 
A latent class analysis was employed to characterize pathology subtypes in MS considering 
quantified pathology (aim 1). Different goodness of fit parameters (AIC, BIC, and G2 statistics) were 
considered to identify the number of classes that better characterize the MS sub-populations. 
 
Differences in stain intensity between pathology profiles (aim 2) were explored using linear mixed 
regression models including group indicator (pathology profile 1, 2 or 3) as main variable of interest, 
and using profile 1 as statistical reference. Fixed effect variables included in the model were 
different stains (NF200, SMI94, CD20, CD3, CD8, CD68, GFAP, IBA1, and percentage of damaged 
 25 
mitochondria, measured as (VDAC-COX4)/VDAC). These models used the cassettes as unit of the 
analysis, with a random subject intercept to account for the nested structure of the data (cassettes 
nested within patients). Results are presented as coefficients (Coeff) and 95% confidence interval 
(95%CI). 
 
Each patient was then classified on the basis of his/her prevalent pathology profile (Table 1). Clinical 
differences between pathology profiles (aim 3) were estimated with chi-square test for categorical 
variables (e.g., functional system at onset, clinical phenotype) and with ANOVA for continuous 
variables (e.g., time to EDSS 7.0 and EDSS 10). 
 
Statistical analyses were performed with Stata 15.0. Statistical significance was set at p<0.05. 
 
4.3 Results 
4.3.1 Pathology profiles of MS 
Three pathology profiles were obtained from latent profile analysis with highest goodness of fit 
parameters (Figure 4). 
 
4.3.2 Pathological correlates of pathology profiles 
When compared with profile 1, profile 2 presented with lower NF200 (Coeff=-3.437; 95%CI:-6.675/-
0.199; p=0.037), SMI94 (Coeff=-10.630; 95%CI=-13.219/-8.041; p<0.001), CD68 (Coeff=-1.149; 
95%CI=-1/427/-0.872; p<0.001), GFAP (Coeff=-52.191; 95%CI=-56.701/-47.682; p<0.001), and IBA1 
(Coeff=-5.150; 95%CI=-7.074/-3.226; p<0.001), and with higher CD8 (Coeff=0.877; 95%CI=0.089-
1.665; p=0.029), and mitochondrial damage (Coeff=54.689; 95%CI=49.929/59.448; p<0.001) (Table 
3; Figure 4; Figure 5).  
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Figure 4. Pathology profiles. 
Representative images are shown from the 3 pathology profiles. NAGM is presented in the upper left corner, with the 
remaining of the image being NAWM (consistently in different images/profiles). In profile 1 (patient 11), 
macrophages/microglia (IBA1) and astrocytes (GFAP) infiltrates were found in the context of relatively normal myelin 
content (SMI94) and in the absence of mitochondrial dysfunction (VDAC) (A-D). In profile 2 (patient 12), an apparently-
normal myelin content (SMI94) was associated with damaged mitochondrial function (VDAC) and with cytotoxic T-
lymphocytes (CD8) infiltrates (mainly perivascular, arrowheads), in absence of significant astrocyte levels (GFAP) (E-H). 
In profile 3 (patient 9), overall levels of myelin (SMI94) were reduced, consistently with mitochondrial function (VDAC), 
in absence of significant infiltrates of macrophages/microglia and astrocytes (I-L). Scale bar is 100 μm. 
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When compared with profile 1, profile 3 presented with lower NF200 (Coeff=-16.798; 95%CI:-
22.206/-11.391; p<0.001), SMI94 (Coeff=-41.498; 95%CI=-45.498/-37.497; p<0.001), GFAP (Coeff=-
18.427; 95%CI=-25.457/-11.396; p<0.001), and IBA1 (Coeff=-5.679; 95%CI=-8.905/-2.454; p=0.001), 
and with higher mitochondrial damage (Coeff=26.507; 95%CI=18.864/34.151; p<0.001) (Table 3; 
Figure 4; Figure 5). 
 
Table 3. Pathological correlates of pathology profiles. 
The table shows pathological correlates of different pathology profiles. Coefficients (Coeff), 95% confidence intervals 
(95%CI) and p-values are shown from mixed effect regression models (with cassettes nested within patients) including 
group indicator (pathology profile 1, 2 or 3) as main variable of interest; profile 1 was used as reference (* indicates 
p<0.05). 
Profile 1 
(reference) 
Profile 2 Profile 3 
 Coeff 95%CI p-values Coeff 95%CI p-values 
  Lower Upper   Lower Upper  
NF200 -3.437 -6.675 -0.199 0.037* -16.798 -22.206 -11.391 0.026* 
SMI94 -10.630 -13.219 -8.041 <0.001* -41.498 -45.498 37.497 <0.001* 
CD20 0.211 -0.284 0.706 0.403 0.077 -0.749 0.905 0.854 
CD3 0.553 -0.100 1.206 0.097 0.340 -0.746 1.428 0.539 
CD8 0.877 0.089 1.665 0.029* 0.408 -0.937 1.754 0.552* 
CD68 -1.149 -1.427 -0.872 <0.001* -0.012 -0.483 0.457 0.957 
GFAP -52.191 -56.701 -47.682 <0.001* -18.427 -25.457 -11.396 <0.001* 
IBA1 -5.150 -7.074 -3.226 <0.001* -5.679 -8.905 -2.454 0.001* 
Damaged 
mitochondria 
54.689 49.929 59.448 <0.001* 26.507 18.864 34.151 <0.001* 
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Figure 5. Pathological correlates of pathology profiles. 
Margins plots show coefficients (Coeff) and 95% confidence intervals (95%CI) from mixed effect regression models (with 
cassettes nested within patients) including group indicator (pathology profile 1, 2 or 3) as main variable of interest; 
profile 1 was used as reference; mean immunostain intensity is presented; p-values are also shown (* indicates p<0.05). 
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4.3.3 Clinical correlates of pathology profiles 
Seven patients were included in profile 1, 7 in profile 2 and 2 in profile 3, in accordance with his/her 
prevalent pathology profile (Table 1). 
 
Most common symptoms at onset were sensory in profile 1 (57.1%), spinal cord in profile 2 (71.4%), 
and optic neuritis and sensory in profile 3 (50% and 50%) (p=0.017). Time to EDSS 7.0 was shorter 
in profile 2 (10.4±4.5 years), when compared with profile 1 (23.4±10.7 years) and 3 (25.5±0.7 years) 
(p=0.012). Time to EDSS 10 was shorter in profile 2 (20.5±6.8), when compared with profile 1 
(32.1±11.7 years) and 3 (38.5±2.1) (p=0.038). No difference in pathology profile distribution was 
found between SPMS and PPMS (p=0.237). 
 
4.4 Discussion 
Our data driven analysis was able to detect three main profiles of MS pathology, each of which 
characterized by specific pathology and clinical correlates. This is the first attempt to classify MS 
pathology by using quantitative immunohistochemistry for a number of pathogenetic mechanisms, 
including NA and lesional WM and GM, applying advanced statistical methods, and validating 
towards clinical features of MS. The possibility to classify each MS patient into his/her pathology 
profile has specific clinical consequences in terms of disease profiling and treatment. 
 
Profile 1 (active remodelling) was characterized by normal-appearing neuro-axonal structures and 
intact energetic metabolism, with high levels of macrophages/microglia and astrocytes, possibly 
contributing to subtle but continuous tissue remodelling and damage (Domingues et al., 2016; 
Kawachi and Lassmann, 2017). Patients in profile 1 presented with relatively benign onset and mild 
progression, corresponding to the presence of inflammatory activity (driven by 
macrophages/microglia) without obvious signs of neurodegeneration (Fred D. Lublin et al., 2014). 
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In this pathology profile, chronic tissue remodelling that macrophages/microglia and astrocytes 
exert, could be treated with medications modulating their function. Of note, currently available 
DMTs minimally affect macrophage/microglia and astrocyte function and, so, this subgroup of 
patients could be considered for trials with medications crossing the blood-brain-barrier and directly 
modulating these cells (Du et al., 2017). 
 
Profile 2 (mitochondrial dysfunction) was characterized by severely impaired mitochondrial 
function, along with demyelination and neuroaxonal loss, and ongoing inflammatory changes, 
mainly driven by cytotoxic T-cells (CD8+). Patients in profile 2 presented with severe symptoms at 
onset and faster disability accrual, corresponding to the presence of inflammation and 
neurodegeneration (Fred D. Lublin et al., 2014). In this pathology profile, the ongoing inflammatory 
activity should be treated with immunomodulatory treatments; interventions aiming to support 
energetic metabolism should also be considered (Campbell and Mahad, 2018). 
 
Finally, profile 3 (inactive) was characterized by severe demyelination and axonal loss, with similarly 
reduced mitochondrial function, without any concomitant pathological process contributing to 
further tissue remodelling and/or damage. Patients in profile 3 presented with relatively benign 
clinical features, corresponding to the absence of disease activity (Fred D. Lublin et al., 2014). In this 
pathology profile, medications with putative neuro-regenerative effects should be evaluated. 
 
Pathogenic mechanisms depicted by our classification are not new and have already been described 
and differently named in previous qualitative studies on lesional and NA MS brain tissue (Table 4) 
(Bö et al., 1994; Bruck et al., 1995; Kuhlmann et al., 2017; Lassmann et al., 1998; Lucchinetti et al., 
2000; Sanders et al., 1993; Van Der Valk and De Groot, 2000). 
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Inflammation was mainly driven by macrophages/microglia in profile 1 and CD8+ cytotoxic T-
lymphocytes in profile 2. However, these cells are generally considered end-effectors of MS 
pathogenesis and a contribution from CD4+ T- and B-lymphocytes should be considered (C. Dendrou 
et al., 2015; Magliozzi et al., 2007; Magliozzi, Howell, et al., 2018). Mitochondrial dysfunction was 
described in profile 2 and 3, and in both cases was associated with neuro-axonal loss. Indeed, 
mitochondrial damage is a marker of chronic cellular dysfunction, can exacerbate inflammation and 
ultimately causes neurodegeneration (Campbell and Mahad, 2018; Haider et al., 2016; Lucchinetti 
et al., 2000; Yang and Dunn, 2018). Finally, in a subset of patients (profile 3, inactive), disease activity 
might eventually cease, leaving signs of previous inflammatory changes (neuro-axonal loss and 
mitochondrial damage) without concomitant pathogenetic changes. 
 
Limitations of the present study include reproducibility on independent and larger samples. The use 
of an independent sample would be helpful to reproduce our results also on tissue with different 
processing and by using different stains. However, latent profile models are very conservative, are 
data driven (and so cannot be affected by any preliminary hypothesis), and are minimally affected 
by sample size. Still, a larger sample size would have allowed more thoughtful clinical correlations. 
 
In conclusion, we defined three main profiles of MS pathology characterized by subtle chronic tissue 
remodelling with diffuse infiltrates of macrophages/microglia and astrocytes (profile 1 – active 
remodelling), mitochondrial dysfunction and active inflammation (profile 2 – mitochondrial 
dysfunction), and chronic tissue damage in absence of active pathogenetic processes (profile 3 – 
inactive). Each profile presented with rather specific clinical correlates. The possibility to classify 
each patient depending on his/her prevalent pathology profile support the concept of MS 
immunopathological homogeneity within the same patient and heterogeneity between different 
patients. Of course, each patient presented with a dominant pathology profile (Table 1), but 
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different pathogenic mechanisms occurred at the same time. In the future, in vivo detection of 
pathology profiles should consider already existing neuroimaging techniques that are able to detect 
the main determinants of each profile (e.g., neuro-axonal/myelin content, microglia, and 
mitochondrial function) (Ciccarelli et al., 2014; J. van Horssen et al., 2012; Marcello Moccia and 
Ciccarelli, 2017). 
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5. Pathological correlates of magnetization transfer ratio in multiple 
sclerosis 
 
5.1 Introduction 
Defining the pathological specificity of MRI techniques improves their usefulness in clinical trial 
design and the interpretation of observational studies (Wattjes et al., 2015). However, post-mortem 
MRI-pathological studies are scarce because of the technical challenges posed by the integration of 
post mortem MRI with histologic analysis, the difficulty in obtaining post mortem material, the long 
duration of scanning, and the need for interpretation of normal post mortem changes (Filippi et al., 
2012). 
 
MTR is an objective index of the capacity of macromolecules to exchange magnetization with the 
surrounding water, indirectly estimating the extent of tissue damage (Mallik et al., 2014). MTR 
values are lower in patients with MS than healthy controls (Bodini et al., 2016), especially in patients 
with progressive MS, and with worse motor and cognitive disability (Stangel et al., 2017). 
Longitudinal evaluation of MTR changes has been used to detect in-vivo a progression of MS 
pathology (Bodini et al., 2016; Chen et al., 2008), and to measure the effect of new medications in 
clinical trials (Brown et al., 2016; Fox, 2018; Romme Christensen et al., 2014). 
 
MTR assessment in these clinical trials has been mostly interpreted as a method to probe myelin 
status within WM lesions (Brown et al., 2016; Schwartzbach et al., 2017), although axonal loss may 
also contribute to MTR changes in MS (Chen et al., 2013; Fisher et al., 2007; Moll et al., 2011; 
Schmierer et al., 2004; Schmierer, Parkes, et al., 2010). Therefore, the main pathological 
determinant of MTR changes remain unclear.  
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We aimed to identify the main histologic correlate(s) of MTR and to investigate whether they varied 
between lesions and NA WM and GM by applying a novel methodology to align MRI to histology 
(Pichat et al., 2018), on a large sample of patient and healthy control brain tissue, with 
comprehensive histology analysis. 
 
5.2 Methods 
5.2.1 Subjects 
Tissue for this study was provided by the United Kingdom MS Tissue Bank at the Imperial College 
London, under ethical approval from the National Research Ethics Committee. The study followed 
Human Tissue Act guidelines. All MS patients (n=16) and controls (n=4) had provided informed 
consent to donate tissue for MS research. Informed consent of the next of kin of the healthy subject 
was obtained before the inclusion of the tissue in this study. The methods are summarized in Figure 
6. 
 
5.2.2 Tissue handling 
From each brain, a single coronal cut through mammillary bodies was done to separate brain into 
anterior and posterior halves. Then, 1 cm-thick coronal slices were cut through entire brain using 
the 1 cm guide and, for the present study, the second slice posterior to the mammillary bodies 
towards the occipital pole was included. Slices were immersed in 10% buffered formaldehyde 
solution for a minimum of seven days, allowing full fixation. 
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Figure 6. Tissue fixation, MRI acquisition, immunohistochemistry, registration and ROI definition. 
In (A), a fixed brain slice on the left and its corresponding MTR image on the right are shown. Several tissue blocks were 
obtained from each slice, based on MRI and visual inspection. An example of a cassette is shown in the white box. In 
(B), digitized quantifiable histological images are shown; they were generated for each stain and aligned spatially (1). 
MRI images were then registered to the space of digitized quantified histological images (2). In (C), different ROIs were 
analysed on both MRI and 
immunohistochemistry. MTR 
image and its corresponding 
immunohistochemistry (white 
box) are presented. Higher 
MTR signal corresponded to 
compact myelin (SMI94, scale 
bar 250μm) in NAWM (red 
asterisk), followed by WM 
lesion (blue asterisk), and 
NAGM (green asterisk). In WM 
lesions, there was reduction in 
neuro-axonal structures 
(NF200, scale bar 50μm), 
astrocyte infiltrates (GFAP, 
scale bar 50μm), and impaired 
mitochondrial function (VDAC, 
scale bar 50μm), compared 
with NAWM. Also, infiltrates 
of microglia/macrophages and 
cytotoxic T-cells were studied 
(IBA1 and CD8, respectively, 
scale bar 50μm).  
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5.2.3 MRI acquisition 
Before scanning, formalin-fixed tissue was washed thoroughly with phosphate-buffered saline 
(PBS), and placed flat in an MRI-compatible container made of Plexiglas and filled with PBS. The MRI 
plane was positioned parallel to the coronal tissue slice. Proton density-weighted (PD), T2-weighted 
(T2) and T1-weighted (T1) spin-echo, and gradient-echo MTR sequences were acquired using a 
clinical scanner (3T Philips Achieva, Philips Healthcare, Best, Netherlands) with a 32-channel head 
coil and multi-transmit technology. The MRI acquisition included the whole 1 cm-thick tissue slice. 
For MTR measurement, two sets of images were obtained using a 3D slab-selective FFE sequence 
with two echoes (TE1/TE2=5.5/12.7ms), with (MS) and without (M0) sinc-Gaussian shaped MT pulses 
of nominal α=360o, offset frequency 1 kHz. Then, MTR maps were calculated using the standard 
equation: (M0−MS/M0)×100. The entire scanning protocol lasted approximately 5 hours and was run 
at room temperature. Further details on MRI acquisitions are given in Table 5. 
 
Table 5. Parameters of MRI sequences 
 Echo Time 
(ms) 
Relaxation time 
(ms) 
Resolution 
(mm) 
Field of View 
(mm) 
PD/T2 12/80 4000 0.25×0.25×2.00 160×160×16 
3D-T1 6.9 15 0.50×0.50×0.50 160×160×60 
MTR 5.5/12.7 37 0.25×0.25×2.00 160×160×60 
MRI: magnetic resonance imaging; PD: proton density-weighted sequence; T2: T2-weighted sequence; 3D-T1: T1-
weighted sequence; MTR: magnetization transfer ratio. 
 
5.2.4 Immunohistochemistry 
After scanning, brain slices were sectioned into different 5 mm-tick tissue blocks (each 
approximately 20×30 mm in size) (101 blocks in 20 cases/controls, on average 5.0 blocks per brain 
slice) (Figure 6A). Blocks' selection was guided by MRI and visual inspection to improve the 
 38 
sensitivity of the selection process (Bö et al., 2004). Serial sections were cut through the block at 5 
μm section thickness using the Tissue-Tek AutoSection automated microtome (Sakura Finetek). 
 
Cassettes were paraffin-embedded and immunostained by IQPath (University College London), 
under the supervision of Prof Sebastian Brandner. Immunostaining was performed using the 
Ventana Discovery XT instrument and the DAB Map detection Kit (760-124), in compliance with 
manufacturer instructions. The cassettes were immunostained and quantified for neuro-axonal 
structures (NF200), myelin (SMI94), macrophages (CD68), B-lymphocytes (CD20), T-lymphocytes 
(CD3), cytotoxic T-lymphocytes (CD8), microglia (IBA1), astrocytes (GFAP), and mitochondrial 
activity (COX4, VDAC). Slides were counterstained with hematoxylin (HE). Details of all 
immunostains are reported in Table 2. Positive and negative controls were included initially when 
optimizing the stains and, then, only positive controls were included when the antigen was not 
expected to be present abundantly in the tissue (e.g., CD immunostains). 
 
Immunostained slides were then digitalized as 8-bit RGB images at 40× magnification using a Leica 
SCN400F slide scanner (Leica Microsystems) (Figure 6B). Digital image analysis was performed with 
Definiens Tissue Studio software 3.6 (Definiens AG, Munich, Germany) (Patodia et al., 2018), with a 
resolution of 5× for tissue identification and a resolution of 10× for stain analysis, taking care to 
exclude any artefacts. Artefacts are excluded from the analysis (e.g., breaks in the section). Images 
were segmented into pixels of 250×250 µm2 (0.0625 mm2). Considering that the degree of 
background staining from secondary antibodies can vary greatly among tissue blocks, the intensity 
threshold for positive labelling was set separately for each immunostain, using an automatic 
histogram method accounting for variation in background stain levels (Otsu, 1979). This histogram 
method finds the optimal threshold by minimizing the intraclass intensity variance, which 
simultaneously maximizes interclass variance. Separate thresholds were set for HE staining which 
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allowed identification of nuclei. Also, the use of nested statistical models further accounted for 
possible inter-subject variability.  
 
For each pixel, immunostain intensity and its coordinates were exported in CSV files, including 
brown intensity for immunostains and blue for HE. 
 
5.2.5 Registration 
For each cassette, the following three steps were applied to obtain a 2D spatial alignment of MRI 
and histology (Figure 6B): 
1) A subject-wise space was created by group-wise registration of digitized histological images, via 
consecutive rounds of rigid, affine and non-linear registrations with NiftyReg (version 1.3.9) 
(Modat et al., 2010, 2014; Pichat et al., 2018); 
2) The T2-weighted image that best resembled a given histological image with good contrast was 
chosen. The selected MR plane was cropped to narrow down the search space and, then, rigid 
registration was performed (Modat et al., 2014). Rigid registration was preferred over non-rigid 
to preserve the original shape of the tissue without deformation, thereby reducing the 
possibility of false correspondences between histology and MRI (Lee et al., 2005; Pichat et al., 
2018); 
3) MRI sequences were brought to the group-wise space by applying the inverse transformation 
from the second step to the selected planes (Modat et al., 2010; Pichat et al., 2018). 
 
5.2.6 Image analysis and data extraction 
Regions-of-interest (ROIs) were manually delineated on the co-registered MRI and histology with 
3D Slicer (version 4.4.0). The detection of ROIs was primarily guided by T2-weighted images, with 
other MR and histological images used as references, to cover the full spectrum of MS pathology 
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(Kilsdonk et al., 2016). Thus, the normal-appearing tissue was identified on MRI images, but 
confirmed on histological images with higher contrast (e.g., NF200, SMI94, IBA1, GFAP, COX4, VDAC) 
(Figure 6C). ROI area was variable depending on the amount of included tissue. The following ROIs 
were drawn (number of included ROIs is reported): NAWM (n=98), WM lesions (n=61), cortical 
NAGM (n=89), and cortical GM lesions (n=50) (on average 2.9±1.8 ROIs per tissue block in MS, and 
1.8±0.4 in controls). Overall, 298 records (from different cases/controls, blocks, and ROIs) were 
included in the statistical models. 
 
Mean MTR signal, mean immunostain intensity (percentage of stained area) and ROI area were 
extracted for each ROI using FSL (version 5.0.9). For data analysis, the intensity of mitochondrial 
immunostains was combined as follows: percentage of damaged mitochondria = (VDAC-
COX4)/VDAC (Roman et al., 2005; Shoshan-Barmatz et al., 2010). 
 
5.2.7 Statistics 
First, we explored population characteristics. Differences in age, gender, death-to-fixation interval 
and cassettes between cases and controls were measured with the chi-square test, Fisher's exact 
test or Mann-Whitney test, as appropriate. Differences in MTR across ROIs, when considering all 
patients and controls together, were measured with linear mixed regression models accounting for 
the hierarchical structure of data (cassettes nested within patients). 
 
Secondly, the association between MTR and each stain (dependent variables) were explored using 
linear mixed regression models. Fixed-effect variables included in the model were MTR, 
demographics (age, gender), group indicator (case/control), factors possibly affecting MTR 
measurement (death-to-fixation interval, T1-weighted values corresponding to the same ROI) 
(Schmierer et al., 2007), and factors possibly affecting histology quantification (ROI area, total cell 
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count as measured on HE counterstain). These models used the cassettes as the unit of the analysis, 
with a random subject intercept to account for the nested structure of the data (cassettes nested 
within patients). In a first model, we additionally fitted an interaction term between group and MTR 
to explore possible differences in the association of MTR and each stain between patients and 
controls. Similarly, an interaction term between ROI (using NAWM as reference) and MTR was set 
to explore possible variations in the association of MTR and each stain between different ROIs. 
 
Finally, to assess the association between MTR and multiple stains simultaneously, so that the 
strongest correlate(s) of MTR values could be detected, we fitted a multivariate linear mixed 
regression model (assuming inter-correlation between stains). As multiple outcomes were 
dependent variables of this model, we selected the stains that were to be significantly associated 
with MTR in previous models. The multivariate linear mixed regression model was fitted using 
generalized structural equation modelling. Residuals were checked to confirm model assumptions. 
Results are presented as coefficients (Coeff), 95% confidence intervals (95%CI) and p-values. 
 
Results were considered statistically significant if p-values were <0.05. Stata 15.0 was used for data 
processing and analysis. 
 
5.3 Results 
The study included 101 tissue blocks from 16 MS brains and four healthy controls, from which we 
derived 298 ROIs. Mean brain weight was 1241.8±151.8 grams. Death-to-fixation interval was 
27.1±11.7 hours. Cases and controls were similar in age, gender, death-to-fixation interval, and the 
number of cassettes (Table 6). Both secondary progressive MS (n=11) and primary progressive MS 
(n=5) brains were studied. 
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Table 6. Characteristics of MS cases and healthy controls. 
 MS 
(n=16) 
Controls 
(n=4) 
p-values 
Age, years 66.1±7.1 72.5±7.8 0.199 
Gender, female (%) 10 (62.5%) 2 (50.0%) 0.535 
Death-to-fixation interval, hours 28.8±11.6 20.2±10.5 0.216 
Cassettes, number from each slice 5.2±1.0 4.5±0.6 0.199 
PPMS/SPMS, number 5/11   
P-values are shown from chi-square test, Fisher's exact test or Mann-Whitney test, as appropriate. 
 
Considering all patients and controls together, MTR values changed across tissue classes, with 
higher values in NAWM (35.7±8.4), followed by WM lesions (32.5±9.0), NAGM (28.3±8.1), and GM 
lesions (26.2±7.4) (all p<0.001) (Figure 7). 
 
Figure 7. MTR values across ROIs. 
Box-and-Whisker plots show mean MTR values across ROIs. P-values are shown form linear mixed regression models 
accounting for the hierarchical structure of data (cassettes nested within patients).  
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When investigating the association between MTR and histological stains in brains of patients and 
controls together, lower MTR values were associated with lower NF200, SMI94, CD68, IBA1, and 
GFAP, with higher CD8, and with a more extensive mitochondrial damage (estimated by combining 
VDAC and COX4). Coefficients, 95%CI and p-values are reported in Table 7 and Figure 8.  
 
When looking at the differences in the associations of MTR and histological stains between patients 
and controls and between ROIs, we found that the relationship between MTR and mitochondrial 
damage was stronger in MS brains when compared with controls (coefficients, 95%CI and p-values 
are reported in Table 7) and that the strength of the associations varied between GM and WM 
regions. In particular, when compared with NAWM, the association between MTR and NF200 was 
stronger in GM lesions, the association between MTR and SMI94 was stronger in NAGM and GM 
lesions, and the association between MTR and mitochondrial damage was stronger in NAGM, 
(coefficients, 95%CI and p-values are reported in Table 7). Additionally, when compared with 
NAWM, the association between MTR and CD68 was less strong in WM lesions, and the association 
between MTR and IBA1 and GFAP was less strong in NAGM and GM lesions (coefficients, 95%CI and 
p-values are reported in Table 7). 
 
In the multivariate linear mixed regression model, MTR was independently associated with SMI94, 
whereas no associations were detected for the remaining stains (coefficients, 95%CI and p-values 
are reported in Table 7). 
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Figure 8. Associations between MTR and immunostains. 
Scatter plots show 
associations between mean 
MTR values (y-axis) and mean 
immunostain intensity (x-
axis) for NF200 (neuro-axonal 
structures, A), SMI94 
(myelin, B), CD68 
(macrophages, C), CD8 
(cytotoxic T-lymphocytes, D), 
IBA1 (microglia, E), GFAP 
(astrocytes, F), and 
mitochondrial damage (G), 
for each ROI (NAWM in red, 
WM lesions in blue, NAGM in 
green, and GM lesions in 
yellow). P-values and 
coefficients are shown from 
linear mixed regression 
models accounting for the 
hierarchical structure of data 
(cassettes nested within 
patients).   
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5.4 Discussion 
The most striking finding of our study is that myelin content was the strongest histologic correlate 
of MTR values, especially when MTR was measured in the GM, and this relationship was 
independent of all other pathological stains. Although MTR is a marker of myelin content in the GM, 
we found that it also has other histologic correlates, including neuro-axonal structures and 
mitochondrial damage in the GM, and macrophages, microglia and astrocytes in the WM. 
Interestingly, the association between MTR and impaired mitochondrial activity was stronger in MS 
cases when compared with controls, thereby expanding the list of imaging biomarkers that, at least 
in part, can reflect mitochondrial impairment (J. van Horssen et al., 2012). 
 
Strengths and novelties of our study, when compared with previous MRI-pathology correlation 
studies, are the breadth of immuno-histochemical stains, the inclusion of brains from both MS 
patients and healthy controls, and the analysis of both lesions and normal-appearing GM and WM. 
Also, our novel semi-automatic registration technique reduced the risk of false correspondence 
between different histology and MRI images, and ultimately enabled the study of antigens not 
expected to be abundantly present within brain tissue (e.g. CD8 presented with 2.7% average 
intensity across different ROIs). 
 
In our dataset, MTR values correlated with markers of myelin and neuro-axonal integrity, but only 
myelin remained significant in a multivariate linear mixed effect model. Demyelination is a common 
feature of MS pathology and can occur independently from axonal loss (as shown by the presence 
of chronically demyelinated axons) (DeLuca et al., 2006; Mottershead et al., 2003; Schmierer et al., 
2004). Also, we found that the association between MTR and myelin content is stronger in both GM 
lesions and NAGM, than NAWM. Probing myelin status in the GM is of great interest considering 
that more axons are demyelinated in the GM (40%), when compared with WM (9%) (Carassiti et al., 
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2017). Our findings extend previous studies where MTR was associated with myelin content and 
axonal loss in the GM (Chen et al., 2013; Jonkman et al., 2016; Schmierer, Parkes, et al., 2010). Of 
note, MTR in WM lesions, which is frequently used as outcome measure in clinical trials (Brown et 
al., 2016; Schwartzbach et al., 2017), could reflect complex pathological changes other than myelin 
content (Vavasour et al., 2011). 
 
With regard to the WM, we found that lower MTR values in the WM reflected lower levels of 
macrophages, microglia and astrocytes. If we assume that low MTR is associated with reduced tissue 
integrity, this result may be seen counterintuitive considering that astrocytes make a major 
contribution to MS pathology by regulating macrophages and microglia towards lesional and peri-
lesional tissue reorganization (Chang et al., 2012; Correale and Farez, 2015; Howell et al., 2010; Prins 
et al., 2015). However, if MTR ranges from low values in the cerebrospinal fluid (0%) to high in 
compact myelin, one could argue that cellular structures, such as astrocytes, microglia and 
macrophages, could move MTR towards higher values, rather than lower (towards water), in 
particular in normal appearing and lesional WM, where these cells are more abundantly present. 
These cells could be responsible for abnormal MRI findings, in presence of mild demyelination or, 
also, in its absence (Trapp et al., 2018). Of note, in the multivariate models, the association between 
MTR and myelin remained stable despite levels of astrocytes, microglia and macrophages, 
suggesting MTR is mainly driven by myelin content but can be affected by complex pathological 
changes occurring in the WM. 
 
Low MTR was associated with markers of mitochondrial damage more in MS brains than controls. 
Mitochondrial dysfunction, with subsequent energy failure and oxidative activation, is considered 
as one of the main determinants of MS pathogenesis (Kawachi and Lassmann, 2017), and might 
contribute to the lower MTR values observed in MS patients than controls. This hypothesis might 
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be further tested in vivo by combining MTR with other imaging techniques detecting mitochondrial 
activity, such as quantification of N-acetyl-aspartate on MR spectroscopy (Ciccarelli et al., 2014; Li 
et al., 2013; Marcello Moccia and Ciccarelli, 2017). 
 
The observed association between low MTR and CD8 T-lymphocyte infiltrates may reflect the 
presence of diffuse chronic inflammation (Frischer et al., 2009). However, inflammatory cells could 
change in distribution depending on disease stage and ROI (Bø et al., 2003; C. Dendrou et al., 2015; 
Frischer et al., 2009), and future studies will explore further the role of the levels of cytotoxic T 
lymphocytes in determining MTR values. 
 
Limitations of this study include formalin fixation and postmortem changes in tissue structure 
(Schmierer et al., 2008; Schmierer, Thavarajah, et al., 2010). After death, T1 relaxation time 
shortens, and this can result in lower MTR (Schmierer et al., 2007). However, we included T1-
weighted values from the corresponding ROI and death-to-fixation interval as covariates in the 
statistical models to reduce this bias. In addition, after formalin fixation, water is removed and its 
contribution to the MTR signal cannot be analysed. However, in our post mortem sample with fixed 
brain tissue, MTR values were 2-3% higher than previous studies on fixed brain tissue, similar to 
previous studies on fresh (unfixed) brain tissue (Schmierer et al., 2008; Schmierer, Thavarajah, et 
al., 2010), and only 5-10% lower than what would be expected in vivo (Filippi et al., 2017). Also, MTR 
was significantly different across ROIs, with higher values being found in NAWM, followed by WM 
lesions, NAGM and GM lesions (Figure 7), as previously described both in vivo and ex vivo (on fixed 
and unfixed brain tissue) (Abdel-Fahim et al., 2014; Chen et al., 2013; Schmierer et al., 2008; 
Schmierer, Thavarajah, et al., 2010). Overall, these findings suggest that we captured reasonably 
good quality data. Imaging co-registration is challenging for histological sections, inevitably suffering 
from structural deformations (Gilmore et al., 2009). In the current study, we used a semi-automatic 
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registration technique to align MRI and histology spatially to reduce inaccuracy in ROI definition, as 
previously described (Lee et al., 2005; Modat et al., 2010, 2014). A qualitative evaluation of cellular 
structures and their interactions, which can provide information on the molecular and biological 
processes associated with MTR, is out of the scope of our study, which includes quantitative 
measurements of both MTR and pathological changes. When all the immunostains were included 
in the same model, myelin was the only significant correlate of MTR, independently from the other 
pathological processes. 
 
In conclusion, myelin integrity is the strongest pathological correlate of MTR. However, MTR values 
in GM also reflect mitochondrial function and neuro-axonal loss, and in WM also monocyte, 
astrocyte and microglia density. These results can be helpful when interpreting MTR findings in 
different brain regions and add pathological specificity in clinical trials aiming to assess the specific 
effect of new medications which can impact on different pathological mechanisms in MS. 
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6. Peripheral markers of oxidative stress and inflammation in multiple 
sclerosis 
 
6.1 Introduction 
Chronic inflammation in MS is one of the processes responsible for increased oxidative stress (Friese 
et al., 2014; Haider et al., 2011; J van Horssen et al., 2012). Products of oxidative damage are 
widespread in MS brains, and have been associated with development of inflammation, 
demyelination and neurodegeneration (Haider et al., 2011; J van Horssen et al., 2012). As such, the 
use of exogenous antioxidants looks particularly promising to treat MS with a multimodal approach, 
also including conventional DMTs (Friese et al., 2014; J van Horssen et al., 2012). Different 
antioxidant therapies have been studied in MS, with the strongest evidence coming from animal 
models for alpha-lipoic acid and epigallocatechin-3-gallate (Plemel et al., 2015), and showed anti-
inflammatory properties, along with neuroprotective and neuroregenerative effects (Adamczyk and 
Adamczyk-Sowa, 2016; Plemel et al., 2015). Thus, targeting oxidative stress could represent a 
valuable therapeutic target for both relapsing-remitting (RR) and progressive MS (De Angelis et al., 
2018). 
 
Coenzyme Q10 (CoQ10) is a cofactor of the mitochondrial oxidative respiratory chain and acts as a 
powerful anti-oxidant and anti-inflammatory compound and, when administered peripherally (e.g. 
oral or intravenous), is able to cross the blood-brain barrier (Belousova et al., 2016; Spindler et al., 
2009). MS patients, in particular those with more severe disease, presented with lower blood levels 
of CoQ10 and, more in general, with higher levels of oxidative stress, when compared with controls 
(Choi et al., 2018; Gironi et al., 2014). When supplementing MS patients with CoQ10 during a 12-
week period, a reduction in peripheral markers of oxidative stress (Sanoobar et al., 2013), and 
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inflammation was noted (Sanoobar et al., 2015), along with improvement of fatigue and depressive 
symptoms (Sanoobar, P Dehghan, et al., 2016).  
 
However, most protocols on anti-oxidant therapies in MS included a limited set of laboratory and 
clinical outcomes of MS (Plemel et al., 2015). Thus, we utilized a wide set of laboratory and clinical 
measures to explore: 1) the effect of CoQ10 supplementation along with Interferon-Beta1a 44μg 
treatment on variations of markers of oxidative stress and inflammation in the peripheral blood 
(primary endpoint); 2) the effect of CoQ10 supplementation along with Interferon-Beta1a 
treatment on variations of clinical measures of MS severity (secondary endpoint); 3) the associations 
between variations of laboratory measures as for CoQ10 supplementation, and clinical outcomes 
(tertiary endpoint). Finally, in a post-hoc analysis of this study, we aimed to define most promising 
peripheral biomarkers of oxidative stress and inflammation by estimating the sample size needed 
to detect their significant variations. 
 
6.2 Methods 
6.2.1 Study design 
This is a retrospective analysis on prospectively collected data, recorded at the MS Clinical Care and 
Research Centre of the “Federico II” University (Naples, Italy). Biological materials and clinical data 
were collected during clinical visits performed according to clinical practice. The study was approved 
by the “Federico II” University Ethics Committee and patients gave informed consent to the study. 
 
Patients having received Interferon-Beta1a alone or with CoQ10 were extracted and assigned to 
either Group1 (CoQ10 supplementation along with Interferon-Beta1a over the first 3 months, 
followed by Interferon-Beta1a alone for 3 months) or Group 2 (Interferon-Beta1a alone over the 
first 3 months, followed by CoQ10 supplementation along with Interferon-Beta1a for 3 months), 
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with a crossover design, in order to obtain groups with similar demographic and clinical features 
(Table 8). This design used within-subjects comparison of treatments and, so, minimised 
confounding by removing any natural biological variation that may have occurred in the 
measurement of the outcome measures (Sedgwick, 2014). 
 
The use of CoQ10 was open label, with patients being aware if on treatment, and no washout 
between the two periods was considered. To minimise any possible bias, our primary outcomes 
were laboratory-based (not affected by the open label design), and were recorded at the end of the 
treatment period; also, a near-immediate switch of treatments was considered (3 months) 
(Sedgwick, 2014). Details of the study design are reported in Figure 9. 
 
Table 8. Baseline demographic and clinical features. 
Table shows demographic and clinical features of treatment groups at baseline. Group1 received CoQ10 
supplementation along with Interferon-Beta1a over the first 3 months, followed by Interferon-Beta1a alone for 3 
months; Group 2 received Interferon-Beta1a alone over the first 3 months, followed by CoQ10 supplementation along 
with Interferon-Beta1a for 3 months. P-values are reported from χ2 test, Fisher’s exact test or t-test (p<0.05 is presented 
as *). 
 
 Group 1 
(n=30) 
Group 2 
(n=30) 
p-values 
Age, years 42.1±10.5 40.9±9.0 0.639 
Gender, female (%) 21 (70%) 21 (70%) 0.999 
Disease duration, years 10.9±2.0 11.1±1.5 0.662 
Baseline EDSS 2.7±1.0 2.6±1.0 0.943 
Naïve patients, number (%) 15 (50%) 15 (50%) 0.999 
Duration of Interferon-Beta1a, years 5.2±4.2 4.5±4.7 0.912 
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Figure 9. Study design. 
A crossover design was considered. Group1 received CoQ10 supplementation along with Interferon-Beta1a over the 
first 3 months, followed by Interferon-Beta1a alone for 3 months; Group 2 received Interferon-Beta1a alone over the 
first 3 months, followed by CoQ10 supplementation along with Interferon-Beta1a for 3 months. 
 
 
6.2.2 Population and CoQ10 supplementation 
Patients had dietary supplementation with 200mg/day CoQ10 during a 3-month period (Figure 9). 
Ubidecarenone formulation was used in compliance with indications for clinical practice (Skatto®, 
100mg/ml, Chiesi Farmaceutici SpA). 
 
Inclusion criteria were: 1) clinical and radiological diagnosis of RRMS with 2010 Revisions to the 
McDonald criteria (Fred D. Lublin et al., 2014; Polman et al., 2011); 2) age>18-year-old; 3) treatment 
with Interferon-Beta1a 44μg. In particular, patients were required to be steadily on treatment with 
Interferon-Beta1a 44μg for at least 6 months before inclusion in the study and, then, for the whole 
study period (3+3 months); patients were either drug-naïve or previously-treated with medications 
other than Interferon-Beta1a 44μg (1:1).  
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Exclusion criteria were: 1) recent relapse or corticosteroid treatment (<6 months); 2) exposure at 
any time to azathioprine, cladribine, cyclophosphamide, cyclosporine A, methotrexate, or any other 
immunosuppressive agent; 3) history of malignancy, major systemic disease or other illness that 
would in our opinion interfere with the interpretation of study results; 4) use of contraceptive drugs; 
5) use of any vitamins, minerals or other over-the-counter compounds; 6) concomitant inclusion in 
any other observational or interventional study.  
 
6.2.3 Laboratory outcomes 
Blood samples have been collected in fasting conditions in lithium heparin tubes. Blood was 
immediately centrifuged and plasma samples were stored at -80oC for a maximum period of 6 
months. Four cc plasma have been processed in order to analyse: 
 - Markers of free radical scavenging activity: uric acid (UA) and bilirubin were measured by 
using the UA2 and the BILTS enzymatic methods, respectively, with the COBAS® c501 
analyser (Roche Diagnostic, Mannheim, Germany); - Markers of serum oxidative damage: 8-hydroxy-2-deoxyguanosine (8-OHdG, an end product 
of oxidative DNA damage) and protein carbonyls (an end product of oxidative protein 
damage) were measured by using the OxiSelect™ Oxidative DNA Damage ELISA kit, and the 
OxiSelect™ Protein Carbonyl ELISA Kit, respectively (Cell Biolabs, San Diego, CA, USA); - Markers of inflammation: the Human Cytokine Magnetic 35-Plex Panel (Invitrogen by 
Thermo Fisher Scientific) was used for the quantitative detection of EGF, Eotaxin, basic-FGF, 
G-CSF, GM-CSF, HGF, IFN-α, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-2R, IL-3, IL-4, IL-5, IL-6, IL-7, IL-
8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17A, IL-17F, IL-22, IP-10, MCP-1, MIG, MIP-1α, MIP-1β, 
RANTES, TNF-α, and VEGF, in compliance with manufacturer’s instructions; samples were 
analysed with a Luminex® 200™. 
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CellROX® Orange Reagent (Life Technologies) was used for measuring intracellular reactive oxygen 
species (ROS) production. Peripheral blood mononuclear cells (PBMCs) were isolated by stratifying 
heparinized whole blood on Ficoll-Hypaque (GE Healthcare). Freshly isolated PBMCs were incubated 
with 5µM CellROX® Orange Reagent for 30 minutes in the dark at 37°C, washed three times and re-
suspended in PBS. The fluorescence was quantified using FACScanto II analyser (Becton–Dickinson, 
San Diego, CA) and Flow-Jo software (Tree Star Inc., Ashland, OR, USA); intracellular ROS production 
(CellROX) was measured as percent positive cells (%) and mean fluorescence intensity (MFI). 
 
6.2.4 Clinical outcomes 
Demographic characteristics (age, gender), concomitant diseases and treatments, and MS clinical 
features (disease duration, occurrence of relapses, EDSS) were recorded. Examiners were certified 
EDSS raters. Patients were classified as drug naïve or previously-treated, in relation to the use of 
Interferon-Beta1a; duration of Interferon-Beta1a treatment was calculated. 
 
6.2.5 Patient-reported outcomes. 
At baseline, 3- and 6-month visits, patients were required to fill in the following questionnaires: 
 - MS neuropsychological questionnaire (MSNQ) is a 15-item questionnaire for self-reporting 
everyday life functioning, neuropsychological functioning, and mood, with higher scores 
indicating a more preserved cognitive function; this is a quick screening tool for cognitive 
impairment (Benedict et al., 2003; O’Brien et al., 2007); an Italian version of the 
questionnaire was preliminary administered to a subset of patients and then used for this 
study; 
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0 to 10, where the individual must indicate severity of pain and headache; this scale is easy-
to-answer and is particularly suitable for exploratory analyses (Tur, 2016); - Fatigue severity scale (FSS) is composed by 9 questions, with higher scores indicating a more 
severe impact of fatigue on daily life activities; this is an easy-to-answer questionnaire that 
can be quickly administered in the clinical practice (Tur, 2016); - Beck's depression inventory (BDI) II consists of 21 items assessing severity of common 
depressive symptoms; for each item, participants are required to choose the point scale 
(from 0 to 3) that best describes how they felt in the last 2 weeks, with higher scores 
indicating the presence of depressive symptoms (Beck et al., 1996). 
 
For each scale, we preferred to use absolute values rather than cut-off points. This is because 
patient-reported outcomes were a secondary endpoint of the study and, accordingly, our inclusion 
criteria did not select a population where such cut-off points would necessarily define homogenous 
groups. On the contrary, absolute values of these scales would better depict variations over time 
and in relation to treatment. 
 
6.2.6 Preliminary sample size calculation 
Considering the main outcome of the present study (variations of laboratory markers in RRMS 
patients evaluated at 3 different time points by using mixed-effect linear regression models), and 
the results obtained in our previous longitudinal study on uric acid in RRMS (M. Moccia, Lanzillo, 
Costabile, et al., 2015), a sample of 60 subjects for a total of 180 records was considered suitable to 
obtain an acceptable estimate (effect size=30%; α=0.05; power=0.9), accepting 20% missing data. 
The present sample is larger than previous studies investigating CoQ10 effects in MS (Sanoobar et 
al., 2013, 2015; Sanoobar, P Dehghan, et al., 2016). 
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6.2.7 Statistical analyses 
Preliminary comparisons between treatment groups were performed with χ2 test, Fisher’s exact test 
or t-test, as appropriate.  
 
To evaluate associations between CoQ10 supplementation and variations of each laboratory 
(primary endpoint) and clinical outcome (secondary endpoint), mixed-effect linear regression 
models were employed to account for multiple measures repeated within each individual 
(laboratory and clinical measures collected at baseline and after 3 and 6 months). The crossover 
model included random effects for patient id, and fixed-effects for time (baseline, 3 and 6 months) 
and for the visit after CoQ10 exposure (post-CoQ10 supplementation measures were collected at 3 
months in Group 1, and at 6 months in Group 2), overall accounting for possible carry-over effects. 
An interaction term between treatment and time (continuous) was set and marginal effects were 
calculated, to estimate treatment-related variations of laboratory and clinical outcomes over time 
in both Group 1 and 2.  
 
To evaluate associations between CoQ10-related variations of laboratory and clinical outcomes 
(tertiary endpoint), we selected laboratory and clinical measures being affected by CoQ10 
supplementation (p<0.05 in previous models). Mixed-effect linear regression models were 
employed to account for multiple measures repeated within each individual. An interaction term 
between treatment group and each laboratory measure was set and marginal effects were 
calculated, to estimate possible associations between CoQ10-related variations of laboratory 
measures and clinical outcomes. 
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Covariates included in the statistical models were age, gender, disease duration, duration of 
Interferon-Beta1a treatment, baseline EDSS and, for analysis of UA levels, creatinine. Results are 
presented as coefficient (Coeff), 95% confidence intervals (95%CI) and p-values. All the variables 
included in the model were tested for multicollinearity (variance inflation factor [VIF] smaller than 
2.5). Laboratory analyses, clinical assessments, and patient-reported scales were run blind to each 
other. The statistician matched the datasets and was blind to treatment codes. 
 
Finally, sample size needed to detect treatment effect on different markers of oxidative stress and 
inflammation was computed using the formula ! = #(%&'%()*),-,., , where n is the required sample 
size per treatment arm in 1:1 controlled trials, Zα and Z1-β are constant (set at 5% alpha-error and 
90% power, respectively), σ is the standard deviation and Δ the estimated effect size (Altmann et 
al., 2009). Effect size was estimated using adjusted-beta-coefficient of 3-month variation for each 
laboratory measure obtained with mixed-effect linear regression models from our previous study 
(including age, gender, disease duration, baseline EDSS, and duration of Interferon-β1a treatment 
as covariates). We assumed that the observed variation, as estimated by adjusted-beta-coefficients, 
was the highest achievable treatment effect (100%) over 3 months. From there, with a conservative 
approach, we hypothesized different treatment effects (e.g., 30%, 50%, 70%, and 90%), that were 
smaller than the observed effect. Standard deviation was calculated from the variation of each 
laboratory measure after 3 months. 
 
Stata 15.0 and Microsoft Excel were used for data processing and analysis. Results have been 
considered statistically significant if p<0.05.  
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6.3 Results  
60 RRMS patients were included in the study. Treatment groups were similar in age, gender, disease 
duration, baseline EDSS, and distribution of naïve/on-treatment patients (Table 8). When 
considering laboratory and clinical measures, missing data were less than 20%, as preliminary 
accounted by sample size calculation. 
 
During the study period, 4 patients presented with a clinical relapse (6.6%), being equally distributed 
in CoQ10-treated and -untreated groups. 
 
6.3.1 CoQ10 supplementation and variations of laboratory measures 
After 3 months, CoQ10 supplementation was associated with increased scavenging activity (uric 
acid, Coeff=0.123; p=0.034), and with reduced intracellular ROS production (%, Coeff=-9.925; 
p=0.021; and MFI, Coeff=-523.308; p<0.001), and DNA damage (8-OHdG, Coeff=-0.630; p=0.049). 
 
Also, after 3 months, CoQ10 supplementation was associated with increased IL-4 (Coeff=-3.883; 
p=0.012) and IL-13 (Coeff=3.732; p=0.006), and with reduced Eotaxin (Coeff=-18.669; p=0.042), GM-
CSF (Coeff=-1.751; p=0.006), HGF (Coeff=-26.397; p=0.015), IFN-γ (Coeff=-1.526; p=0.027), IL-1α 
(Coeff=-2.460; p=0.040), IL-2R (Coeff=-29.971; p=0.016), IL-9 (Coeff=-3.749; p=0.023), IL-17F 
(Coeff=-68.854; p=0.034), MIP-1α (Coeff=-5.327 ; p=0.044), RANTES (Coeff=-2331.281 ; p=0.002), 
TNF-α (Coeff=-1.795; p=0.024), and VEGF (Coeff=-0.398; p=0.042) (Table 9; Figure 10). 
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Table 9. Variations of laboratory outcomes in relation to CoQ10 supplementation. 
Table shows variations of different laboratory outcomes after coenzyme Q10 supplementation along with Inteferon-
Beta1a, compared with Inteferon-Beta1a alone. Laboratory measures repeated within each individual at baseline and 
after 3 and 6 months were included in mixed-effect linear regression models where we set an interaction term between 
time and treatment period (post-CoQ10 supplementation visit was at 3 months in Group 1, and at 6 months in Group 
2). Coefficients (Coeff), 95% confidence intervals (95%CI) and p-values are reported (p<0.05 is presented as *). 
Primary endpoints Coeff 95%CI p-values 
Lower Upper  
Markers of scavenging activity     
Uric acid, mg/dL 0.123 0.009 0.237 0.034* 
Bilirubin, mg/dL 0.066 -0.042 0.174 0.232 
Markers of oxidative damage     
CellROX cells, % -9.925 018.353 -1.497 0.021* 
CellROX cells, MFI -523.308 -758.793 -287.822 <0.001* 
Protein carbonyls, nmol/mg -0.266 -1.320 0.787 0.620 
8-OHdG, ng/mL -0.630 -1.294 -0.034 0.049* 
Markers of inflammation     
EGF, pg/mL -3.637 -17.291 10.016 0.602 
Eotaxin, pg/mL -18.669 -36.643 -0.695 0.042* 
Basic-FGF, pg/mL -2.736 -24.007 18.535 0.801 
G-CSF, pg/mL -4.692 -16.508 7.124 0.436 
GM-CSF, pg/mL -1.751 -2.959 -0.455 0.006* 
HGF, pg/mL -26.397 -56.213 -13.418 0.015* 
IFN-α, pg/mL 1.780 -22.515 26.077 0.886 
IFN-γ, pg/mL -1.526 -2.878 -0.175 0.027* 
IL-1α, pg/mL -2.460 -5.313 -0.591 0.040* 
IL-1β, pg/mL -1.188 -3.531 1.153 0.320 
IL-1RA, pg/mL -10.464 -38.999 18.070 0.472 
IL-2, pg/mL 5.099 -11.619 21.817 0.550 
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IL-2R, pg/mL -29.971 -54.330 -5.612 0.016* 
IL-3, pg/mL 28.661 -68.832 126.155 0.564 
IL-4, pg/mL 3.883 0.843 6.923 0.012* 
IL-5, pg/mL -12.890 -34.403 8.621 0.240 
IL-6, pg/mL 5.559 -46.568 57.687 0.834 
IL-7, pg/mL -16.428 -42.050 9.193 0.209 
IL-8, pg/mL -11.418 -23.830 0.993 0.071 
IL-9, pg/mL -3.749 -8.057 -1.557 0.023* 
IL-10, pg/mL 1615.546 -1399.093 4630.185 0.294 
IL-12, pg/mL 2.498 -11.569 16.566 0.728 
IL-13, pg/mL 3.732 1.045 6.419 0.006* 
IL-15, pg/mL 21.693 -37.211 80.597 0.470 
IL-17A, pg/mL -0.453 -1.508 0.602 0.400 
IL-17F, pg/mL -68.854 -140.017 -12.307 0.034* 
IL-22, pg/mL -8.406 -68.069 51.255 0.782 
IP-10, pg/mL 5.699 -44.344 55.743 0.823 
MCP-1, pg/mL 39.540 -45.290 124.371 0.361 
MIG, pg/mL -5.409 -19.197 8.379 0.442 
MIP-1α, pg/mL -5.327 -10.515 -0.138 0.044* 
MIP-1β, pg/mL 17.125 -49.443 83.695 0.614 
RANTES, pg/mL -2331.281 -3772.510 890.052 0.002* 
TNF-α, pg/mL -1.795 -3.595 -0.468 0.024* 
VEGF, pg/mL -0.398 -0.821 -0.052 0.042* 
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Figure 10. Laboratory outcomes. 
Profile plots show variations of laboratory outcomes over time in relation to the use of Interferon-Beta1a alone or in 
combination with Coenzyme Q10 (Group 1: group receiving Coenzyme Q10 from baseline to 3-month follow-up is in 
red; Group 2: group receiving Coenzyme Q10 from 3- to 6-month follow-up is in green). Coefficients (Coeff) and p-values 
are shown from mixed-effect linear regression models where an interaction term between treatment and time was set 
and marginal effects were calculated. 
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6.3.2 CoQ10 supplementation and variations of clinical outcomes 
After 3 months, CoQ10 supplementation was associated with reduction of EDSS (Coeff=-0.227; 
p=0.036), FSS (Coeff=-4.527; p=0.027), BDI (Coeff=-3.544; p=0.022), and VAS for pain (Coeff=-1.318; 
p=0.049) (Table 10; Figure 11). 
 
 
Table 10. Variations of clinical and patient-reported outcomes in relation to CoQ10 supplementation. 
Table shows variations of different clinical and patient-reported outcomes (range of scales is reported) after coenzyme 
Q10 supplementation along with Inteferon-Beta1a, compared with Inteferon-Beta1a alone. Clinical measures repeated 
within each individual at baseline and after 3 and 6 months were included in mixed-effect linear regression models 
where we set an interaction term between time and treatment period (post-CoQ10 supplementation visit was at 3 
months in Group 1, and at 6 months in Group 2). Coefficients (Coeff), 95% confidence intervals (95%CI) and p-values are 
reported (p<0.05 is presented as *). 
Secondary endpoints Coeff 95%CI p-values 
Lower Upper  
Clinical outcomes     
EDSS (0-10) -0.227 -0.438 0.015 0.036* 
Naïve patients 0.014 -0.251 0.222 0.915 
Patient-reported outcomes     
MSNQ (0-60) 1.946 -3.655 7.548 0.496 
FSS (9-63) -4.527 -9.424 -1.368 0.027* 
BDI (0-63) -3.544 -7.212 -1.124 0.022* 
VAS for pain (0-10) -1.318 -2.691 -0.054 0.049* 
VAS for headache (0-10) -0.909 -2.359 0.541 0.219 
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Figure 11. Clinical outcomes. 
Profile plots show variations of clinical outcomes over time in relation to the use of Interferon-Beta1a alone or in 
combination with Coenzyme Q10 (Group 1: group receiving Coenzyme Q10 from baseline to 3-month follow-up is in 
red; Group 2: group receiving Coenzyme Q10 from 3- to 6-month follow-up is in green). Coefficients (Coeff) and p-values 
are shown from mixed-effect linear regression models where an interaction term between treatment and time was set 
and marginal effects were calculated. 
 
 
6.3.3 Variations of laboratory and clinical outcomes 
Reduction in EDSS was associated with CoQ10 effect on reduced intracellular ROS production (MFI, 
Coeff=0.001; p=0.001), and IFN-γ (Coeff=0.126; p=0.009), and on increased IL-13 (Coeff=-0.057; 
p=0.028). Reduction in FSS was associated with CoQ10 effect on reduced intracellular ROS 
production (%, Coeff=0.232; p=0.023). Reduction in BDI was associated with CoQ10 effect on 
increased uric acid (Coeff=-1.665; p=0.049). Reduction in VAS for pain was associated with CoQ10 
effect on reduced IL-1α (Coeff=0.127; p=0.043), and RANTES (Coeff=0.001; p=0.009), and on 
increased IL-4 (Coeff=-0.075; p=0.024). 
 
Full results are reported in Table 11. 
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Table 11. Variations of clinical outcomes in relation to CoQ10-related effects on laboratory measures. 
Table shows variations of different clinical outcomes in relation to coenzyme Q10 (CoQ10) effects on laboratory 
measures. Laboratory and clinical measures repeated within each individual at baseline and after 3 and 6 months were 
included in mixed-effect linear regression models where we set an interaction term between time and treatment period 
(post-CoQ10 supplementation visit was at 3 months in Group 1, and at 6 months in Group 2). Coefficients (Coeff), 95% 
confidence intervals (95%CI) and p-values are reported (p<0.05 is presented as *). 
Tertiary endpoints Coeff 95%CI p-values 
Lower Upper  
EDSS     
Uric acid, mg/dL -0.045 -0.118 0.027 0.224 
CellROX cells, % 0.036 -0.059 0.133 0.457 
CellROX cells, MFI 0.001 0.001 0.004 0.001* 
8-OHdG, ng/mL 0.095 -0.012 0.203 0.084 
Eotaxin, pg/mL 0.049 -0.037 0.136 0.268 
GM-CSF, pg/mL 0.055 -0.035 0.146 0.232 
HGF, pg/mL 0.052 -0.034 0.138 0.236 
IFN-γ, pg/mL 0.126 0.031 0.222 0.009* 
IL-1α, pg/mL 0.047 -0.038 0.133 0.274 
IL-2R, pg/mL 0.057 -0.027 0.141 0.186 
IL-4, pg/mL 0.050 -0.036 0.137 0.258 
IL-9, pg/mL 0.049 -0.039 0.137 0.275 
IL-13, pg/mL -0.057 -0.107 -0.006 0.028* 
IL-17F, pg/mL 0.044 -0.043 0.133 0.320 
MIP-1α, pg/mL 0.050 -0.0351 0.136 0.246 
RANTES, pg/mL 0.053 -0.-34 0.141 0.233 
TNF-α, pg/mL 0.053 -0.033 0.139 0.229 
VEGF, pg/mL 0.049 -0.039 0.137 0.278 
FSS     
Uric acid, mg/dL -0.430 -2.244 1.383 0.642 
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CellROX cells, % 0.232 0.071 0,473 0.023* 
CellROX cells, MFI 0.241 -2.015 2.498 0.834 
8-OHdG, ng/mL 0.045 -1.777 1.868 0.961 
Eotaxin, pg/mL 0.072 -1.707 1.853 0.936 
GM-CSF, pg/mL 0.484 -1.428 2.397 0.620 
HGF, pg/mL 0.060 -1.743 1.864 0.948 
IFN-γ, pg/mL -0.004 -1.891 1.882 0.996 
IL-1α, pg/mL 0.006 -1.810 1.822 0.995 
IL-2R, pg/mL -0.029 -1.870 1.810 0.975 
IL-4, pg/mL 0.044 -1.777 1.865 0.962 
IL-9, pg/mL -0.013 -1.868 1.841 0.989 
IL-13, pg/mL 0.112 -1.708 1.933 0.904 
IL-17F, pg/mL 0.004 -1.854 1.862 0.997 
MIP-1α, pg/mL 0.024 -1.793 1.843 0.979 
RANTES, pg/mL 0.141 -1.721 2.003 0.882 
TNF-α, pg/mL 0.006 -1.823 1.836 0.995 
VEGF, pg/mL -0.070 -1.926 1.785 0.941 
BDI     
Uric acid, mg/dL -1.665 -3.326 -0.004 0.049* 
CellROX cells, % -0.205 01.664 1.253 0.782 
CellROX cells, MFI -0.145 -1.766 1.475 0.860 
8-OHdG, ng/mL 0.439 -0.841 1.720 0.501 
Eotaxin, pg/mL 0.424 -0.867 1.716 0.520 
GM-CSF, pg/mL 0.546 -0.833 1.926 0.438 
HGF, pg/mL 0.431 -0.864 1.727 0.514 
IFN-γ, pg/mL 0.322 -0.993 1.637 0.631 
IL-1α, pg/mL 0.388 -0.908 1.684 0.557 
IL-2R, pg/mL 0.310 -0.979 1.599 0.637 
IL-4, pg/mL 0.390 -0.894 1.674 0.552 
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IL-9, pg/mL 0.232 -1.053 1.523 0.720 
IL-13, pg/mL 0.291 -1.000 1.583 0.658 
IL-17F, pg/mL 0.271 -1.028 1.572 0.682 
MIP-1α, pg/mL 0.365 -0.922 1.652 0.578 
RANTES, pg/mL 0.170 -1.142 1.483 0.799 
TNF-α, pg/mL 0.362 -0.936 1.662 0.584 
VEGF, pg/mL 0.166 -1.111 1.443 0.799 
VAS for pain     
Uric acid, mg/dL -0.230 -0.816 0.355 0.441 
CellROX cells, % 0.254 -0.329 0.838 0.393 
CellROX cells, MFI 0.015 -0.629 0.660 0.963 
8-OHdG, ng/mL 0.124 -0.374 0.623 0.625 
Eotaxin, pg/mL 0.143 -0.370 0.657 0.585 
GM-CSF, pg/mL 0.262 -0.267 0.792 0.332 
HGF, pg/mL 0.156 -0.362 0.674 0.555 
IFN-γ, pg/mL 0.201 -0.330 0.733 0.458 
IL-1α, pg/mL 0.127 0.004 0.251 0.043* 
IL-2R, pg/mL 0.164 -0.357 0.687 0.537 
IL-4, pg/mL -0.075 -0.141 -0.009 0.024* 
IL-9, pg/mL 0.125 -0.395 0.646 0.636 
IL-13, pg/mL 0.178 -0.335 0.692 0.497 
IL-17F, pg/mL 0.140 -0.377 0.658 0.594 
MIP-1α, pg/mL 0.064 -0.004 0.133 0.066 
RANTES, pg/mL 0.001 0.001 0.001 0.009* 
TNF-α, pg/mL 0.149 -0.366 0.664 0.570 
VEGF, pg/mL 0.139 -0.385 0.664 0.603 
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6.3.3 Sample size estimates for peripheral biomarkers of oxidative stress and inflammation in 
relapsing-remitting multiple sclerosis 
 
Setting the power at 80% and alpha at 5%, low sample size requirements to detect 70% variation 
from a baseline pre-treatment timepoint to a 3-month follow-up were found for IL-3 (n=1), IL-5 
(n=1), IL-7 (n=4), IL-2R (n=4), IL-13 (n=6), IL-6 (n=14), IL-8 (n=22), IL-4 (n=23), RANTES (n=25), TNF-α 
(n=26), IL-1β (n=27), and uric acid (n=29). Other investigated markers presented with a sample size 
per treatment arm larger than 30 (Figure 12; Table 12). 
 
Table 12. Sample size estimates for treatment arm for 3-month variations of peripheral biomarkers of oxidative stress 
and inflammation. 
Table shows beta-coefficients (Coeff) and standard deviations (SD) used for the sample size calculation (derived from 
our previous study). Sample per treatment arm is reported, hypothesizing 70% treatment effect, compared with 
observed treatment effect, over 3 months. Power was set at 80% and alpha at 5%. 
 Coeff. SD Sample size 
(70% treatment effect) 
Markers of scavenging activity    
Uric acid, mg/dL 0.123 0.117 29 
Bilirubin, mg/dL 0.066 0.190 265 
Markers of oxidative damage    
CellROX cells, % -9.925 11.25 41 
CellROX cells, MFI -523.308 1124.538 148 
Protein carbonyls, nmol/mg -0.266 1.393 878 
8-OHdG, ng/mL -0.630 0.708 40 
Markers of inflammation    
EGF, pg/mL -3.637 8.513 175 
Eotaxin, pg/mL -18.669 31.968 94 
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Basic-FGF, pg/mL -2.736 4.863 101 
G-CSF, pg/mL -4.692 61.503 5498 
GM-CSF, pg/mL -1.751 2.524 66 
HGF, pg/mL -26.397 33.925 53 
IFN-α, pg/mL 1.780 11.498 1335 
IFN-γ, pg/mL -1.526 1.937 52 
IL-1α, pg/mL -2.460 2.526 34 
IL-1β, pg/mL -1.188 1.096 27 
IL-1RA, pg/mL -10.464 18.329 98 
IL-2, pg/mL 5.099 14.090 244 
IL-2R, pg/mL -29.971 11.182 4 
IL-3, pg/mL 28.661 4.276 1 
IL-4, pg/mL 3.883 3.317 23 
IL-5, pg/mL -12.890 2.069 1 
IL-6, pg/mL 5.559 3.671 14 
IL-7, pg/mL -16.428 5.639 4 
IL-8, pg/mL -11.418 9.425 22 
IL-9, pg/mL -3.749 4.212 40 
IL-10, pg/mL 1615.546 2417.951 72 
IL-12, pg/mL 2.498 14.365 1058 
IL-13, pg/mL 3.732 1.628 6 
IL-15, pg/mL 21.693 21.658 32 
IL-17A, pg/mL -0.453 0.941 138 
IL-17F, pg/mL -68.854 72.039 35 
IL-22, pg/mL -8.406 40.134 729 
IP-10, pg/mL 5.699 30.460 914 
MCP-1, pg/mL 39.540 96.247 190 
MIG, pg/mL -5.409 13.555 201 
MIP-1α, pg/mL -5.327 5.338 32 
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MIP-1β, pg/mL 17.125 17.060 32 
RANTES, pg/mL -2331.281 2041.081 25 
TNF-α, pg/mL -1.795 1.608 26 
VEGF, pg/mL -0.398 0.519 54 
 
Figure 12. Profile plot for sample size estimates for treatment arm. 
Figure shows sample size for most 
promising laboratory markers of 
oxidative stress and inflammation 
(<30 patients for treatment arm, 
with 70% treatment effect). 
Sample size is reported 
hypothesizing 30%, 50%, 70% and 
90% treatment effect. Power was 
set at 80% and alpha at 5%. 
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6.4 Discussion 
Supplementation with CoQ10 in RRMS patients treated with Interferon-Beta1a 44μg was associated 
with improved scavenging activity, reduced oxidative damage and anti-inflammatory changes in the 
peripheral blood, and with clinical improvement in depressive symptoms, disability, pain and 
fatigue. When compared with previous investigations on the same topic, the present study included 
a wider set of laboratory and clinical outcomes, and attempted to relate variations in clinical 
measures to laboratory changes, in order to shed light on relationships between oxidative stress, 
inflammation and MS clinical features. 
 
The use of CoQ10 was associated with increased levels of uric acid in the peripheral blood, a natural 
antioxidant responsible for a large amount of serum scavenging activity. Uric acid levels are 
generally lower in MS, when compared with controls, possibly as a consequence of chronic oxidative 
stimuli (Marcello Moccia, Lanzillo, Palladino, et al., 2015). During Interferon-Beta treatment, uric 
acid is expected to progressively decrease, in particular in patients presenting with clinical relapses, 
disability progression or cognitive worsening (M Moccia, Lanzillo, Costabile, et al., 2015). In our 
population, we might argue that antioxidant effects of CoQ10 contributed to restoring serum 
scavenging activity, ultimately leading to reduction of depressive symptoms, as measured by BDI. 
Of note, this is the first report of association between uric acid and depression in MS, whereas this 
has been shown already for other neurological disorders (i.e., Parkinson’s disease) (Marcello 
Moccia, Picillo, Erro, et al., 2015). 
 
After 3-month CoQ10 supplementation, we observed an improved oxidative balance, with reduction 
of intracellular ROS production and of oxidative DNA damage in the peripheral blood. Oxidative 
damage in inflammatory cells and in DNA is a main driver of MS pathology (Haider et al., 2011; J van 
Horssen et al., 2012), and, accordingly, we found reduction of intracellular ROS production being 
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associated with improvement in fatigue and disability. The possibility to reduce oxidative damage 
and its clinical consequences by using CoQ10 along with DMTs looks particularly promising and 
deserves to be investigated in future studies with dedicated design. 
 
CoQ10 supplementation reduced pro-inflammatory cytokines towards a more anti-inflammatory 
environment in the peripheral blood. We observed a reduction of cytokines determining chronic 
inflammation within the central nervous system (i.e., GM-CSF, IFN-γ, IL1-α, IL-2R, IL-9, IL-17F, TNF-
α) (Becher et al., 2017; C. A. Dendrou et al., 2015; Elyaman and Khoury, 2017; Göbel et al., 2018; 
Liddelow et al., 2017), of chemokines suppressing the activity of microglia towards brain repair (i.e., 
MIP-1α, RANTES) (Huber et al., 2018; Pittaluga, 2017), and of molecules enhancing lymphocyte 
activity and subsequent brain damage (i.e., HGF, VEGF) (Benkhoucha et al., 2013; Girolamo et al., 
2014; Molnarfi et al., 2012). At the same time, we showed an increase of IL-4 and IL-13, that exert 
a neuroprotective role through suppression of pathologically-active macrophages and microglia 
(Göbel et al., 2018; Guglielmetti et al., 2016). Previous studies associated modifications towards an 
anti-inflammatory environment with improved clinical and radiological outcomes of MS (Magliozzi, 
Howell, et al., 2018; Rossi et al., 2017). However, we have to acknowledge that these molecules are 
highly related to each other (Becher et al., 2017; C. A. Dendrou et al., 2015; Elyaman and Khoury, 
2017; Liddelow et al., 2017), and direct effects of CoQ10 are hard to distinguish from its indirect, 
exerted through a general improvement of the oxidative balance. 
 
Based on present results, we estimated sample size to detect significant variations for future study 
design. Most promising inflammatory biomarkers are strongly related to MS pathogenesis, and, in 
particular, to acute (e.g., IL-1β, IL-3) and chronic inflammation (e.g., IL-2R, IL-6, IL-7, IL-8, TNF-α) 
within the central nervous system (Göbel et al., 2018; Lee et al., 2018; Lin and Edelson, 2017; 
Stampanoni Bassi et al., 2018; Tavakolpour, 2016), to suppression of the activity of microglia 
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towards brain repair (i.e., RANTES), and to neuroprotective modulation of pathologically-active 
macrophages and microglia (e.g., IL-4, IL-13) (Göbel et al., 2018; Guglielmetti et al., 2016). Markers 
of oxidative stress also resulted in rather small sample sizes, with particular regard to markers of 
serum scavenging activity (uric acid), and of oxidative damage in inflammatory cells and DNA 
(CellROX % and 8-OHdG). Not least, biomarkers of oxidative stress and inflammation included in the 
present study were previously associated with MS clinical features (Göbel et al., 2018; M Moccia, 
Lanzillo, Costabile, et al., 2015; Marcello Moccia, Lanzillo, Palladino, et al., 2015; Moccia et al., 2018), 
were related to the risk of MS (Tavakolpour, 2016), and have also been used as therapeutic targets 
(Göbel et al., 2018). Overall, peripheral biomarkers of inflammation, scavenging activity and 
oxidative damage gave realistically achievable sample size estimates, and could be used in 
exploratory clinical trials and observational studies to screen new or already existing medications 
with putative effects on inflammation and oxidative stress, over 3-month time. Current sample size 
calculations were rather conservative. We assumed observed treatment effect was 100% effect, and 
our estimates were based on smaller effects than what we actually observed. However, greater 
treatment effects could be hypothesized with different medications and doses, leading to smaller 
sample size. 
 
The present study also included clinical outcomes as exploratory secondary endpoints. After CoQ10 
supplementation along with Interferon-Beta1a 44μg, patients presented with lower depressive 
symptoms, disability, fatigue and pain. The association between CoQ10 and improvement in 
depression has already been described in MS (Sanoobar, Parvin Dehghan, et al., 2016), and could 
be related to CoQ10 effects on serotonin pathways (Abuelezz et al., 2017). Improvement in disability 
as measured by EDSS is hard to explain considering that baseline EDSS values were relatively low, 
study duration was 6 months and sustained changes would require longer observation time (Kalincik 
et al., 2015). Thus, it is possible that short-term variations in EDSS could reflect physiological 
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fluctuations and/or were at least in part related to improvement of fatigue, as already described 
during CoQ10 supplementation in MS (Sanoobar, Parvin Dehghan, et al., 2016), rather than a 
sustained improvement of disability. CoQ10 looks effective in reducing painful symptoms in other 
conditions (Cordero et al., 2012), and its use in MS should be further explored with more 
appropriate scales.  
 
The main limitation of the present study is the open-label design, considering that patients had 
CoQ10 supplementation according to clinical practice. However, the primary outcome of the study 
was the measurement of laboratory variations that cannot be influenced by the open-label design 
and that were associated with clinical changes. Previous studies in MS used higher CoQ10 dosage 
(Sanoobar et al., 2013, 2015; Sanoobar, Parvin Dehghan, et al., 2016); however, at 200mg/day, we 
were able to detect significant changes on both laboratory and clinical measures in a relatively short 
time. Additional markers of MS severity could have been included (e.g., MRI data), but follow-up 
should have been longer than 3-month treatment duration to observe meaningful changes. Some 
of the effects we described for CoQ10 could be attributable to Interferon-Beta1a (Molnarfi et al., 
2012; Zoghi et al., 2011), and their separate contribution is hard to analyse; we included duration 
of Interferon-Beta1a in the statistical models but this did not apparently affect study results. We 
only collected peripheral blood but, considering that CoQ10 is able to penetrate the central nervous 
system (Belousova et al., 2016; Spindler et al., 2009), we might hypothesize that similar effects could 
be observed centrally.  
 
In conclusion, the present study showed that the use of CoQ10 in RRMS patients treated with 
Interferon-Beta1a 44μg improved the oxidative balance and reduced the inflammatory 
environment in the peripheral blood, along with clinical benefits. Peripheral biomarkers of oxidative 
stress and inflammation could be used in exploratory, proof-of-concept studies aiming to evaluate 
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the profile of activity of new or already existing medications. Medications with putative anti-oxidant 
and anti-inflammatory effects could be tested in a short time (3 months) and on small samples (<30 
per treatment arm), before being moved towards larger clinical trials requiring longer observation 
time and larger samples.  
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7. Conclusions and future perspectives 
 
The present thesis explored MS pathogenesis comprehensively, by including both post mortem and 
in vivo studies, and a wide set of pathology markers. Our results can be helpful in understanding 
immunopathological heterogeneity of MS, in interpreting more thoughtfully MRI findings, and in 
designing future clinical trials and observational studies. 
 
In the first part of the study, we applied a data-driven approach to define three profiles of MS 
pathology characterized by subtle chronic tissue remodelling with diffuse infiltrates of 
macrophages/microglia and astrocytes (profile 1 – active remodelling), mitochondrial dysfunction 
and active inflammation (profile 2 – mitochondrial dysfunction), and chronic tissue damage in 
absence of active pathogenetic processes (profile 3 – inactive). Each profile presented with rather 
specific clinical correlates. Afterwards, we performed pathological validation of MTR, and showed 
that myelin is the strongest correlate of MTR. However, MTR signal also reflects the variety of 
pathological changes occurring in MS and, in particular, mitochondrial function and neuro-axonal 
loss in GM, and monocyte, astrocyte and microglia infiltrates in WM. Finally, we showed the effect 
of CoQ10 on markers of oxidative stress and inflammation in the peripheral blood, suggesting that 
these biomarkers could be used in exploratory, proof-of-concept studies aiming to evaluate the 
profile of action of new or already existing medications. 
 
In the future, knowledge acquired from our post mortem studies could be used for a more reliable 
and reproducible in vivo detection of MS pathology. A more thoughtful knowledge of MS pathology 
along with pathological validation of measures that can be acquired in vivo, might shed light on 
mechanisms of action of new medications, and could be included in clinical trials aiming to explore 
drug potentials for neuroprotection and tissue repair (Ruggieri et al., 2017). Neuroimaging 
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techniques that reflect different pathology mechanisms of MS (e.g., neuro-axonal/myelin content, 
microglia, and mitochondrial function) (Ciccarelli et al., 2014; J. van Horssen et al., 2012; Marcello 
Moccia and Ciccarelli, 2017), could be combined with biomarkers from accessible body fluids (e.g., 
serum or CSF) (Magliozzi, Howell, et al., 2018), in order to profile the dominant pathology in each 
patient. Translating these results into clinical trials and practice would mean the identification of 
groups of patients who are more likely to respond to a medication, and the individualized 
monitoring of treatment response. Also, such comprehensive evaluation might help in patient 
stratification and, so, in further reducing the sample size needed in clinical trials by improving 
inclusion/exclusion criteria. This possibility is a cornerstone in patient profiling and monitoring, and 
in the development of life-changing treatments.  
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